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Abstract 
In the past, many bioactive natural products were found to be 
immunomodulators. Although considerable attention has been devoted 
to the investigation of new immunomodulators, there is very little 
information on the immunomodulatory effect of bacterial capsular 
polysaccharides. 
In my study, K24 Capsular Polysaccharide (K24 CPS), with known 
structure of repeating unit, was isolated from the capsule of Klebsiella 
pneumoniae serotype K24 and found to be non-toxic by the brine shrimp 
assay. 
K24 CPS exhibited mitogenic effect on murine splenocytes in a dose-
dependent manner in vitro and in vivo and increased the interleukin-2 
(IL-2) production of splenocytes. Injection of K24 CPS into mice could 
augment the cytotoxic activities of murine splenic natural killer C ^ ) 
cells on YAC-1 cells and murine splenic lymphokine-activated killer 
(LAK) cells on LAK-sensitive but NK-resistant WEHM64 cells. 
Furthermore, it increased the interleukin-1 (IL-1), tumour necrosis factor 
(TNF-a) and nitric oxide (NO) production of thioglycollate-elicited 
murine peritoneal macrophage. In addition, K24 CPS enhanced the in 
vivo migration of macrophage in to the peritoneal cavity. 
Furthermore, K24 CPS had cytostatic effect on the proliferation of 
Ehlrlich Ascites Tumour (EAT) cells in vitro. Result indicated that K24 
CPS could not alter the cell cycle distribution of EAT cells. The . 
cytostatic effect ofK24 CPS might be mediated by reducing the level of 
phosphotyrosine and phosphothreonine proteins and that of the 
transcription factor, c-jun but not c-fos, which may then alter siganal for 
the proliferation of EAT cells. 
And, it could significantly suppress the EAT growth in vivo. Besides, 
K24 CPS would have immunorestorative activity on the EAT-bearing 
mice and greatly increase the survival time ofEAT-bearing mice. These 
observations indicate that the suppression of EAT growth may be 
mediated by the host immune system. K24 CPS may activate 
reticuloendothelial system, NK cells or other cytokine release to 
suppress the EAT growth. 
Moreover, K24 CPS stimulated the in vitro proliferation ofmurine bone 
marrow cells in a dose-dependent manner. It also induced the 
differentiation of murine bone marrow cells with macrophage 
characteristics. 
In conclusion, our results suggested that K24 CPS possesses 
immunomodulatory and anti-tumour activities. It is hoped that further 
characterization of the K24 CPS would provide an alternative way for 
cancer therapy. 
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Immunomodulation can be defined as the modulation of the immune 
system by certain agents, known as immunomodulators which can alter 
the ability of an animal to trigger an immune response against pathogens 
or tumours. 
Immunotherapy aims at enhancing the anti-tumour response in cancer 
patients using immunomodulators. Immunotherapy can be divided into 
two categories, active and passive. Active immunotherapy is the 
stimulation of the host cellular or humoral anti-tumour immunity. 
Passive immunotherapy is based on the administration of biologically 
active agents with innate anti-tumour properties such as antibodies 
which reacts with growth factor receptors of tumour cells. 
Nowadays, a variety of crude biological extracts of plants, animals and 
bacteria substances of different degrees of purity, cloned cytokines and 
highly purified immunoglobulins have been used as immunomodulators. 
Immunomodulators can be classified into different categories 
(Table.1.1). 
1.2 Effector cells mediating anti-tumour immunity 
The immune system is the body defence system which consists of a 
number of organs and various cell types which have evoked to fight 
against invading microorganisms as well as attacking malignant cells 
and other foreign cells. The cells of the immune system arise from . 
pluripotent stem cells through two main lines of differentiation: the 
lymphoid lineage producing lymphocytes and the myeloid lineage. 
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Table 1.1 Examples of immunomodulators 
Bacterial Preparations Bacillus Calmette Guerin (BCG), C. 
parvum 
Extracts of microorganisms Methanol extractable residue ofBCG 
Chemically identified bacterial Lipopolysaccharide (LPS), Muramyl 
extracts dipeptide 
Chemically identified fungal Glucan 
extracts 
Cytokines IFN-a, IFN-P, IFN-y, IL-2, TNF-a 
Monoclonal Antibodies Monoclonal antibodies to growth-
promoting factors, Anti-tumour antibody 
Extracts of Chinese Herbal Extracts of Pseudostellaria heterophylla 
Medicine (Wong, et al., 1994a) 
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producing phagocytes including monocytes and polymorphonuclear 
granulocytes (neutrophils, eosinophils and basophils) (Hillman et al., 
1992). Cytotoxic T lymphocytes appear to be the most important killer 
cells. Other lymphatic cells, such as natural killer fNFK) cells and 
lymphokine-activated killer (LAK) cells, tumour infiltrating 
lymphocytes (TILs) as well as macrophages are also highly effective in 
the lysis of certain tumour targets. Although the immune surveillance 
mechanisms involving the above effector cells, tumour cells often do 
escape destruction and kill the host. The failure of immunosurveillance 
may be due to the antigenic heterogeneity of the original tumour, the 
shedding of tumour antigens, and host-mediated immunosuppression. 
The aim of tumour immunology research therefore includes the 
elucidation of the mechanism(s) of tumour cell destruction by cytotoxic 
effector cells, its regulation, and the development of methods for 
increasing cellular immunity to tumours suitable for clinical application 
(HillmaneM/., 1992). 
1.2.1 Cytotoxic T Lymphocytes 
Cytotoxic T lymphocytes (CTLs) are a subpopulation of T cells with 
immunological specificity for antigens expressed by virus-infected cells, 
tumour cells or even parasites (Katz, 1977). The majority of CTLs 
express the CD8 molecule and specifically recognize foreign peptides 
derived from intracellularly synthesized antigens associated with self 
class I MHC molecules. The function of differentiated CTLs involves 
the lysis of target cells. The mechanism of CTL mediated anti-tumour 
lysis involves three key features: (1) CTL killing is antigen-specific, ( 2 ) ‘ 
CTL killing requires cell contact, (3) CTLs themselves are not injured 
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during lysis of target cells. The lysis process includes two parallel sets 
of changes. Firstly, CTLs develop specific membrane-bound 
cytoplasmic granules. These granules contain several macromolecules, 
including a membrane pore-forming protein called perforin or cytolysin; 
a series of enyzmes (serine esterases) that contain reactive serines in 
their active sites; a protein toxin, which is either identical or structurally 
related to lymphotoxin (LT); and proteoglycans. Secondly, activated 
CTLs develop the capacity to transcribe and secrete cytokines such as 
IFN-y, LT and other proteins to kill the tumour cells (Groscurth, 1989). 
1.2.2 Macrophages 
Macrophages are potentially important cellular mediators of anti-tumour 
immunity. The activated macrophages preferentially recognize and 
destroy tumour cells and not normal cells in vitro (Adams and Somers, 
1985; Keller et al,, 1986). They also express class II MHC antigens and 
acts as antigen-presenting cells for T cells. Macrophages can be 
activated by lymphokines released by antigen-activated T lymphocytes. 
Activated macrophages can cause the lysis of target cells by antibody-
dependent cell cytotoxicity (ADCC) in which antibodies are directed 
against specific cell surface molecules. Macrophages express Fcx 
receptors and they can be targeted to tumour cells coated with antibody. 
A variety of macrophage products, such as proteases (Adams, 1980), 
interleukin-1 (Onozaki et al., 1985)，reactive oxygen intermediates 
G^athan, 1982) and nitric oxide (Tayeh and Marietta, 1989) may be 
involved in macrophage-mediated cytotoxicity. There is also convincing 
evidence that a major component of macrophage-mediated killing of 
tumours is due to TNF-a secretion (Old, 1988). ‘ 
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1.2.3 Natural Killer Cells 
NK cells are a subset of lymphocytes found in blood and lymphoid 
tissues, such as spleen. NK cells, like all lympho-haematopoietic cells, 
are derived from the bone marrow and appear as large lymphocytes with 
numerous cytoplasmic granules and are sometimes called large granular 
lymphocytes (LGLs) C^ieminen and Saksela., 1985). NK cells do not 
express the CD3 antigen or any of the known T cell receptor chains (a, 
3, y or 5) on their surface but they do express CD16 and CD56 surface 
antigens in humans, and NK-1.1/2.1 in mice (Yu et al., 1992). The NK-
1.1 antigen is by far the best marker in defining murine NK cells (Koo et 
al., 1986). It is expressed on all CD3" NK cells capable of lysing the 
YAC-1 lymphoma cells, a prototypic target for both rat and mouse NK 
cells. 
NK cells possess the ability to kill certain tumour cells or normal cells 
which are infected by virus. The killing activity ofNK cells is "natural". 
It is not induced by specific antigen and is thus part of natural rather 
than specific immunity. These cells mediate cytolytic reactions even in 
the absence of class I or class II MHC antigens on the target cells. NK 
cells can lyse certain tumour cell lines, particularly of haematopoietic 
origin, but not of others. The killing mechanism of target cells by NK 
cells involves granule exocytosis and secretion of a perforin. The 
perforin causes a channel or ring-like hole to be introduced into the 
target structure. The perforin may alternatively make a channel which 
then allows a toxin to enter the target cell and kill it (Herberman et al.,‘ 
1986). NK granules also contain cytotoxins, serine esterases and 
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proteoglycans. NK cells also synthesize TNF-a but not lymphotoxin 
(LT) (Herberman et al., 1986). There appears to be a degree of 
specificity in the tumour-killing activity of NK cells. Moreover, NK 
cells can be targeted to antibody-coated cells because they express low-
affinity Fc receptors (CD16) for IgG molecules. The tumoricidal activity 
ofNK cells is increased by cytokines, including interferons, TNF-a and 
IL-2. Therefore, their role in anti-tumour immunity may depend on the 
concurrent stimulation of T cells and macrophages which produce these 
cytokines (Herberman et al., 1986). More recent studies found that the 
combination of IL-4 and IL-12 (cytotoxic lymphocyte maturation 
factory^K cell stimulatory factor) resulted in a synergistic proliferative 
activity (8-fold) in the CD56+ NK cells (Naume et al., 1993). 
1.2.4 Lymphokine-activated Killer (LAK) 
The precursors of murine lymphokine-activated killer (LAK) can be 
divided into two major subsets : NK-like (CD8_, NK1.1+, asialo GM1+) 
and T-like (CD8+, NK1.1", asialo GM1+). LAK effectors have 
generally been characterized as being either CD8+ or NK1.1^ (Ballas 
and Rasmussen, 1990) It has been shown that in vitro cultivation of 
lymphatic cells including NK cells (CD16+), T cells (CD3+) and even B 
cells (CD20+) in the presence of IL-2 results in the formation of potent 
cytotoxic cells called LAK cells which are able to lyse a wide spectrum 
of target cells (Damle and Bradley, 1988). Unlike NK cells, the LAK 
cells also lyse normal cell types including epithelial cells. In clinical 
trial, LAK cell therapy involves the in vitro generation of LAK cells by 
culturing peripheral blood leukocytes removed from tumour patients in 
high concentrations of IL-2. The LAK cells are then reinjected into the • 
patient (Rosenberg et al., 1987). Adoptive therapy with autologous LAK 
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cells, in combination with in vivo administration of IL-2 or 
chemotherapeutic drugs, has had impressive anti-tumour activities in 
tumour-bearing mice (Yamasaki et al., 1989). Human LAK therapy 
trials have been largely limited to advanced cases of metastatic tumours 
and the efficacy of this approach has not been fully elucidated 
(Rosenberg et al., 1987). 
1.3 Cytokines as immunomodulators in cancer therapy 
Cytokines are a group oflow molecular weight proteins of glycoproteins 
that are involved in the regulation of cell proliferaion and 
differentiation. They also act as important mediators in the coordination 
of immune and inflammatory responses (Arai et al., 1990; Aggarwal and 
Pocsik, 1992). They are produced locally by a variety of cell types and 
act in an autocrine or paracrine manner. Cytokines are pleiotropic and 
exert hormone-like actions both within and outside the immune system. 
Some cytokines are known to be cytostatic and/or cytotoxic to tumours 
and capable of modulating host's immunity to cancer cells. A brief 
overview of the current status of cytokines used as immunomodulators 
in cancer therapy is given below (Foon, 1989; Gutterman, 1988; Mihich, 
1986; Oldham, 1984; Parkinson, 1989). 
1.3.1 Tumour Necrosis Factor-a (TNF-a) 
TNF-a is a growth factor for fibroblasts but it is responsible for 
cachexia in cancer patients. It is mainly released from macrophages and 
monocytes. Activated mouse peritoneal macrophages (obtained from an 
inflammatory exudate) release about 10 times more TNF-a than 
peritoneal "resident" or "elicited" macrophages. Lymphocytes, mast 
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cells, polymorphonuclear leukocytes (PMN), keratinocytes, astrocytes, 
microglial cells, smooth muscle cells, intestinal paneth cells and tumour 
cells (Vassalli, 1992) have also been reported to release TNF-a. Its anti-
tumour effect is very potent in animal systems (Old, 1988,1990). The 
possible mechanism of the endogenous production of TNF-a involves 
the primed and elicited stages at the molecular level. The “primed，，stage 
involves the transcription and translation of precursor TNF-a. The 
‘‘elicited，，stage involves the processing of the preformed precursor 
TNF-a by lysosomal enzyme such as protease which is released from 
lysosome by and eliciting agent and the release of mature TNF-a. 
Usually the eliciting agent is a strong lysosome labilizer such as 
lipopolysaccharide (Mizuno, 1992). 
Phase I and II clinical trials of cancer therapy with human recombinant 
TNF-a have been disappointing for its low effectiveness but severe side 
effects. However, clinical studies of human recombinant TNF-a in 
combination with chemotherapy or other cytokines such as IFN-y and 
IL-2 have not been well established (Frei and Spriggs, 1989; Spriggs 
and Yates, 1992; Taguchi, 1990). A clinical studies indicated that 
intratumoural administration of recombinant human TNF-a exhibited 
potent anti-tumour effects (Taguchi, et al., 1992). Kato et al (1990) 
reported an alternative approach of using recombinant TNF-a as a 
primer to produce endogenous TNF-a and OK-432 as a trigger for 
endogenous production of TNF-a in cancer patients. This endogenous 
TNF-a therapy was effective in treating against metastatic lung or liver 
tumours. 
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1.3.2 Interleukin-1 (IL-1) 
IL-1 is a proinflammatory molecule produced mainly by activated 
macrophages. It acts on target cells both directly and via the induction of 
other cytokines such as IL-6, TNF-a, GM-CSF, M-CSF, G-CSF. 
Besides, it synergizes with TNF-a in a wide variety of biological 
effects. The therapeutical potentials of IL-1 may be attributed to its 
radioprotective approach effect, enhancement of haematopoiesis and 
stimulation ofT cells andNK cells (Haworth and Feldmann, 1991). IL-1 
has anti-tumour effect in several different ways: 
1. by exhibiting direct cytostatic and cytotoxic effect on various murine 
syngeneic tumours (Lachman et al., 1986; Nakamura et al., 1986; 
Onozaki etal., 1985). 
2. by increasing the production of other lymphokines, such as IL-2 and 
interferon. 
3. by enhancing the effect ofNK cells and cytotoxic T lymphocytes 
(CTL) and synergizing with IL-2 and interferon in promoting NK 
and CTL cell activities (Wilmott and Kaplan, 1990). Moreover, IL-1 
had been shown to function as an adjuvant in specific 
immunotherapy resulting in enhanced host survival following 
subsequent tumour challenge (McCune et al., 1990). 
1.3.3 Interleukin-2 (IL-2) 
IL-2 is produced by activated T cells, and its receptor is also found on T 
cells. IL-2 activated killer cells recognized autologous tumour cells. The 
killer cells are called lymphokine-activated killer (LAK) cells with anti-
tumour activities (Damle and Bradley, 1988). Their anti-tumour -
activities can also be enhanced by TNF-a and IFN-y (Maghazachi, 
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1990). IL-1 has been shown to synergize with IL-2 in the generation of 
LAK cells (Crump et al., 1989). IL-2 can also synergize with IFN-y 
(Kim and Wamaka, 1991) or TNF-a (Agah et al., 1988) for treating 
cancers. A potentially exciting approach to IL-2 therapy involves the 
application of IL-2 fusion proteins. Genetic construction of a fusion 
protein involving the receptor binding domain of IL-2 and the toxin 
moiety ofdiphtheria toxin can selectively kill the cells bearing the high-
affinity IL-2 receptor (Murphy et aL, 1986). Clinical trials of IL-2 
begins for treatment of HIV infection by administrating IL-2 before 
overt immunodeficiency develops because IL-2 activated T cells and 
NK cells which can kill the HIV-infected cells (Smith, 1990). 
1.3.4 GranulocytesyMacrophages Colony-Stimulating Factors 
Colony-Stimulating factors are glycoprotein growth factors that control 
survival, proliferation, and differentiation of haematopoietic progenitor 
cells in vitro (Metcalf, 1986). Granulocytes-Macrophages Colony-
Stimulating Factors (GM-CSF) influences the functioning of mature 
cells belonging to the neutrophil/eosinophil and monocyte/macrophage 
lineages (Grabstein et al., 1986). Since these cell types exhibit 
microbicidal and tumoricidal activities, the in vivo application of GM-
CSF is expected to possibly increase resistance against infections and 
also to modulate tumour growth (Herrmann et al., 1989). GM-CSF has 
been demonstrated to be active in leukopenic patients with various 
disease states to cause dose-dependent increase in circulating 
neutrophils, eosinophils, and monocytes (Brandt et al .,1988). In 
addition, the murine WEHI-3B (D+) cells and human leukemic cells 
classified as M2, M3, M4 were induced by human G-CSF to undergo -
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terminal differentiation to macrophages and granulocytes (Souza et al., 
1986). 
1.4 Polysaccharides as potential immunostimulating agents 
Extracts of certain fungi and plants may be of assistance in the treatment 
of cancer. Many of these have been found to possess potent 
immunostimulating activity. In many cases, the activity is due to 
polysaccharides. The polysaccharides are usually composed of glucose, 
mannose, xylose and fructose or mixture ofthese sugars. 
The polysaccharides act as immunostimulators mainly through two 
distinct mechanisms, activation of macrophages and activation of T 
cells. Certain carbohydrates such as acemannan extracted from the pulp 
ofthe Aloe vera plant, acted on both macrophages and T cells (Womble 
and Heldermann, 1988). Recent findings showed that levans and certain 
polysaccharides extracted from chinese herbal medicine, 
Pseudostellaria heterophylla, also activate B cells (Wong et al., 1992b). 
Some mannans and glucans were potent anti-cancer agents. The factors 
that determine whether a polysaccharide would have anti-tumour 
activity were still unclear. For soluble D-glucans, it had anti-tumour 
activity as long as it was linear in structure, without excessively long 
branches. 
In animal studies, i.v. administration of glucan could inhibit the growth 
of a murine allogeneic adenocarcinoma and increase tumour 
macrophage populations. The glucan did not only decrease the number 
of hepatic metastases, but also the size of the primary tumour. It could 
suppress the growth and metastasis of a reticulum cell sarcoma 
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significantly in combination with LAK cells (DiLuzio, 1983). The above 
therapy also increased splenic NK cell activity and Kupffer cell 
tumoricidal activity. 
Saccharomyces glucan probably exerted its anti-tumour effects by 
activating macrophages, including hepatic, splenic and peritoneal 
macrophages. The macrophages were stimulated to produce soluble 
factors such as interleukin-1 and tumour necrosis factor. Therefore, 
macrophages from glucan-treated animals had been shown to release 
factors that were cytotoxic to tumour cells. 
It was evident that many complex carbohydrates, especially those 
extracted traditional herbs, could have immunostimulating activity 
which may be of use in treating cancer (Yamada, 1989). However, the 
concepts about the structure-function relationship of this kind of 
polysaccharide is still very obscure. 
1.5 General properties ofKlebsiellapneumoniae 
Bacteria of the genus Klebsiella belongs to the family of 
Enterobacteriaceae. Approximately 80 types of Klebsiella are 
recognized on the basis of immunochemical tests. One of the 
characteristic of Klebsiella bacteria is the formation of well defined 
capsules which are antigenic and polysaccharide in nature. Capsular 
polysaccharide antigens play an important role in the virulence of the 
bacteria (Simoons-Smit et al., 1986) 
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Klebsiella pneumoniae is the most commonly isolated member of the 
genus Klebsiella. It causes pneumonia. It is nonmotile and grows on 
agar plate as large, moist and slimy colonies. 
The encapsulated strains have characteristic capsules which mainly 
consist of negatively charged acidic polysaccharides. Different types of 
CPS are produced by different strains of Klebsiella pneumoniae and can 
be differentiated serologically. The capsule enables the bacterium to 
resist phagocytosis and inhibit complement activation, therefore, 
encapsulated strains are more virulent. 
Encapsulated Klebsiella pneumoniae serotype K24 has K24 capsular 
polysaccharide (K24 CPS) with known structure of its repeating unit. 
The repeating unit consists of five sugar units, one glucuronic acid 
molecule , one glucose molecule and three mannose molecules ofwhich 
three are linked by a-D-glycosidic bonds and two by P-D- glycosidic 
bonds (Fig.1.1) (Choy et al., 1973). Athamna et al, (1991) indicated that 
five capsular polysaccharides isolated from five Klebsiella pneumoniae 
serotypes K21a, K24, K7, K62 and K70 containing the repeating 
sequence Mana2/3Man or L-Rhaa2/3-L-Rha bound to a marmose/A -^
acetylglucosamine-specific lectin of macrophages, which serves as 
receptor for non-opsonic phagocytosis of mannose-coated particles. No 
binding to the macrophages occurred with five Klebsiella pneumoniae 
serotypes K1, K2, K12, K32, and K55 lacking this disaccharides in their 
capsular polysaccharides. They suggest that Klebsiella pneumoniae 
undergo lectinophagocytosis mediated by disaccharides in their capsular 
polysaccharides recognized by the mannose/A^-acetylglucosamine-
specific lectin of macrophages. It was observed that capsular 
polysaccharides of the two serotypes, K7 and K24, bound to 
macrophage while the parent bacteria did not. It may be explained by 
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assuming that on the bacteria, the required structures, Mana2/3Man are 
inaccessible to the macrophage surface lectin. This notion is supported 
by evidence that cell-cell interaction is dependent upon the spatial 
arrangement and accessibility of the ligands and receptors on the 
respective cells. 
Klebsiella pneumoniae serotype K7 bacteria had been shown to 
stimulate the human polymorphonuclear leukocytes (Podchun et al., 
1992). Whether the capsular polysaccharide or whole bacteria can 
activate other immune response remains to be investigated. Wang et al. 
(1994) reported that Klebsiella can induce thymic atrophy in mice 
probably through the production of tumour necrosis factor-a (TNF-a). 
They further found that this effect can be observed both in 
lipopolysaccharide (LPS)-responder (C3H/HeN) and LPS-non responder 
(C3HyHeJ). The findings implied that LPS in Klebsiella is not essential 
component which stimulate the release ofTNF-a by the immune system 
of the mice. 
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D-GlcA: D-Glucuronic Acid 
D-Man: D-Mannose 
D-Glc : D-Glucose 
Figure 1.1 The structure of the repeating unit of capsular 
polysaccharide of Klebsiella pneumoniae serotype K24 (K24 
CPS). 
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2. Aim and scope of this dissertation 
In the past, many bioactive natural products were found to have 
immunostimulating and anti-tumour activities. Although considerable 
attention has been devoted to the investigation of new 
immunostimulators such as extracts of Pseudostellaria heterophylla 
(Wong et al., 1992b, 1994a), Bupleuri radix (Kok et al., 1995), there is 
very little information on the immunomodulatory effect and anti-tumour 
activities ofbacterial capsular polysaccharides. 
Extracts of Pseudostellaria heterophylla was found to be heterogeneous 
in carbohydrate content with unknown polysaccharide structure and 
contain large amount of glucuronic acid moieties that may play a role in 
immunomodulation. In this connection, it leads to the searching of 
another glucuronic acid-containing polysaccharide of other biological 
origins and testing whether it can modulate immune function. 
In my research project, capsular polysaccharide of Klebsiella 
pneumoniae serotype K24, which also contains glucuronic acid, was 
chosen and its immunomodulatory and anti-tumour effects were studied. 
In addition, Athamna et al. (1991) observed that capsular 
polysaccharides of the two serotypes, K7 and K24, bound to 
macrophage while the parent bacteria did not. It may be explained by 
assuming that on the bacteria, the required structures, Mana2/3Man are 
inaccessible to the macrophage surface lectin. This notion is supported 
by evidence that cell-cell interaction is dependent upon the spatial 
arrangement and accessibility of the ligands and receptors on the 
respective cells. From this finding, capsular polysaccharide of Klebsiella 
pneumoniae serotype K24 other than the parent bacteria was involved in 
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the recognition by macrophages, suggesting that capsular polysaccharide 
ofKlebsiella pneumoniae serotype K24 (K24 CPS) may be recognized 
by the other immune cells and thus may activate the immune response of 
the host and has potential in playing a role in immunostimulation and 
anti-tumour activity. 
The studies ofthe immunostimulating effect and anti-tumour activity of 
K24 CPS on animal system are carried out using cell cultures and 
animal models. The underlying mechanisms of these effects may also be 
explored so that it may provide an alternative way for cancer therapy. 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Animals 
Inbred female BALB/c mice and outbred ICR mice were bred at the 
University Animal House, The Chinese University ofHong Kong. They 
were fed by animal diet (Chow 5001, Rodent Laboratory) and tap water 
ad libitum. Mice of the same age (6-8 weeks old) were used in each 
experiment. 
3.1.2 Klebsiella pneumoniae K24 
Klebsiella pneumoniae K24 culture were obtained from Dr. 0rshov, 
Copenhagen, Denmark. 
3.1.3 Cell lines 
Fibroblast-like tumours 
These include L929 (a transformed fibroblast cell line derived from C3H 
mice) and WEHI-164 (a methylcholantrene-induced fibrosarcoma 
derived from BALB/c mice). L929 cells were kept in RPMI medium 
supplemented with 50 units/ml penicillin, 100 i^g/ml streptomycin and 
10 % Fetal CalfSemm (FCS). 
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Lymphoid tumour 
It includes YAC-1 (a Moloney virus-induced T cell lymphoma of A/Sn 
mice. 
Carcinoma 
Ehrlich Ascites Carcinoma (EAT) is an ascites derivative of a 
spontaneous murine mammary adenocarcinoma (tetraploid subline Ny 
Klein Strain). 
3.1.4 Buffer, Culture media and Chemicals 
Phosphate-buffered saline (PBS) 
PBS was prepared by dissolving 8.00 g NaCl, 0.20 g KC1, 0.20 g 
KH2PO4 and 1.15 g Na2HPO4 in 1 L double distilled water. The pH of 
the solution was adjusted to 7.4 before use. PBS was sterilized by 
autoclaving at 1210C for 15 min. 
Hank's Balanced Salt Solution (HBSS) 
HBSS was prepared by dissolving 0.40 g KC1, 0.06 g KH2PO4, 8.00 g 
NaCl, 0.35 gNaHCO3, 0.12 gN%HP04.12H20, l.OOgD-glucose in 1 
L double distilled water. The pH of the solution was adjusted to 7.2 and 
sterilized by filtration through a 0.22 i^m millipore membrane filter. . 
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Culture Medium 
RPMI 1640 medium (Sigma Chemical Co., USA with 25 mM HEPES) 
was used. The powder medium was dissolved in double distilled water 
and buffered with 25 mM NaHCO3 according to the manufacturer's 
specification. The solution was sterilized by filtration through a 0.22 ^m 
millipore membrane filter. The plain medium was stored at 40C. During 
cell culture, the plain medium was supplemented with 50 units/ml 
penicillin, 100 ^ig/ml streptomycin and 10 % FCS (RPMI complete 
medium). 
Fetal Calf Serum 
Fetal calfserum (Gibco, USA) was stored at -20^C as 50 ml aliquots. 
Normal Saline 
Normal saline was prepared by dissolving 9.00 g NaCl in 1 L double 
distilled water and sterilized by autoclaving at 121^0 for 15 min. 
Scintillation Fluid 
Scintillant was prepared by mixing 12.0 g PPO (Sigma Chemical Co., 
USA), 1.2 g POPOP (Sigma Chemical Co., USA), 2.0 L toluene and 1.0 
L triton X-100. The suspension was stirred overnight until all PPO and 
POPOP were completely dissolved. -
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Dye Solutions 
Neutral Red Solution 
The dye solution was prepared by dissolving 0.5 g neutral red powder 
(Sigma Chemical Co., USA) in 100 ml normal saline. The undissolved 
dye was filtered through Whatman No. 1 filter paper. 
Trypan Blue Solution 
The dye solution was prepared by dissolving 0.3 g trypan blue powder 
(Sigma Chemical Co., USA) in 100 ml normal saline. The undissolved 
dye was filtered through Whatman No.l filter paper. 
Lipopolysaccharide (LPS) 
LPS (E. Coli serotype 0127:B8, Sigma Chemical Co., USA) was 
dissloved in PBS at 1000 i^g/ml and was stored at -20OC until use. 
Dextran 
Dextran {Leuconostoc mesenteroides stain numberB-512, average 
molecular weight 5,000,000-40,000,000) was dissloved in PBS at 1000 
^g/ml and was stored at -20^C until use. 
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Interleukin-lp, Interleukin-2, Interleukin-3 and Tumour Necrosis 
Factor-a 
The above recombinant (E.coli) cytokines were purchased from 
Boehringer Mannheim Biochemica. 
Bovine Serum Albumin (BSA) 
Albumin, Bovine (initial fractionation by heat shock, Fraction V, 
minimum 98 %, electrophoresis, Sigma Chemical Co., USA) was 
dissloved in PBS at 2000 [ig/ml when use. 
Greiss Reagent 
The reagent was freshly prepared by dissolving 0.1 g sulphanilamide 
(Sigma Chemical Co., USA), 0.01 g napthylethylenediamine 
dihydrochloride (Sigma Chemical Co., USA) in 25 % H3PO4 (RDH). 
Solutions for Westem Analysis 
Lysis Buffer 
Lysis buffer was freshly prepared by mixing the stock solutions as 
follows and stored on ice before use. 
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^tnck solutions Volume Final Concentration 
IX PBS 9 ml 
2.1mg/ml Aprotinin 100^ d 21^g/ml Aprotinm 
lmg/ml Leupeptin 5^ il 0.5 i^g/ml Leupeptin 
4..9MMgCl, lO i^l 4.9mM MgCl, 
lOOmMm Sodium Meta-Vanadate lOO^ il lmM Vanvdate 
10% Triton X-100 1ml 1% Triton 
10QmMPMSF M ^ lmMPMSF — 
Total volume 10ml 
PBS containing lmMMeta-vanadate 
PBS containing lmM Meta-vanadate was freshly prepared by mixing 
100ml PBS with 1 ml 100mM Meta-Vanadate and stored on ice 
before use. 
2X SDS Sample Buffer with Bromophenol Blue and 
Mercaptoethanol (pH 6.8) 
It was prepared by dissolving 1.51 g Tris Base, 20.0 g Glycerol, 4.6 g 
SDS, 10.0 ml 2-Mercaptoethanol in 90ml double-distilled water. 
Protein Assay 
BCA protein Assay Reagent A and Reagent B (4% CuSO4(H2O)was 
purchased from PIERCE. 
Protein Electrophoresis 
8 % or 12 % acrylamide lower gel solution was prepared as follows. 
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Amount needp-d for 2 small 2els §%. 12% 
Double-distilled Water 7.63 ml 5.5 ml 
30% Acrylamide 
(Sigma Chemical Co., St. Louis, MO) 4.27 ml 6.4 ml 
4X Lower Gel Buffer 4 ml 4 ml 
TEMED (Gibco, USA) 18.6 ^1 18.6 i^l 
10% Ammonium Persulphate 80 |il 80 M-1 
(Sigma Chemical Co., St. Louis, MO) 
Total Volume (-5ml/gel) 15.9986ml 15.9986ml 
4.5 % acrylamide upper gel solution was prepared as follows. 
Amount needed for 2 small 2els 4.5 % _ 
Double-distilled Water 4.8 ml 
30% acrylamide (Sigma Chemical Co., St. Louis, MO) 1.2 ml 
4X Upper gel buffer 2.0 ml 
TEMED (Gibco, USA) 10.6 |il 
10% Ammonium Persulphate 
(Sigma Chemical Co., St. Louis, MO) ^ ^ 
Total Volume 8.07 ml 
4X Lower Gel Buffer (pH 8.8) 
It was prepared by dissolving 90.8 g Tris Base, 2.0 g SDS in 400ml 
double-distilled water. pH was adjusted to 6.8 before making up to 500 
ml with double-distilled water and stored at 4 °C. 
4X Upper Gel Buffer (pH 6.8) 
It was prepared by dissolving 30.3 g Tris Base, 2.0 g SDS in 400ml 
double-distilled water. pH was adjusted to 6.8 before making up to 500 
ml with double-distilled water and stored at 4 °C. 
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10X SDS Running Buffer 
It was prepared by dissolving 30.3 g Tris Base, 10.0 g SDS, 144.0 g 
Glycine in 1000ml double-distilled water and stored at RT. The working 
concentration is IX. 
IX SDS Sample Buffer with p-mercaptoethanol & Bromophenol 
Blue 
It was prepared by dissolving 0.757 g Tris Base, 10.0 g Glycerol, 10 ml 
2-Mercaptoethanol, and 2.3 g SDS in 80ml double-distilled water. pH 
was adjusted to 6.8 before making up to 100 ml with double-distilled 
water and stored at RT. 
Electrobloting 
Electroblot Buffer 
It was prepared by mixing 66.7 ml 10X Tris-Glycine (pH8.3), 100 ml 
methanol, 500 ml dd water. 
lOXTris-Glycine (pH8.3) 
It was prepared by dissolving 30.3 g Tris Base, 144.0 g Glycine in 
1000ml double-distilled water and stored at RT. ‘ 
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Antibody Probing 
5% non fat dry milk (freshly prepared each time). 
l X P B S containing 0.1% Tween 20 (PBS-T) 
It was prepared by mixing 3996 ml PBS with 4 ml Tween 20 and stored 
atRT. 
10% Thimerosal (RT) (5 ml) 
It was prepared by dissolving 0.5 g thimerosal in 5 ml dd water and 
stored at RT. 
Blot Development and Detection 
ECL Western Blotting Detection Reagents 1 & 2 (Amersham) was 
purchased. 
Antibodies 
Anti-phosphotyrosine antibody (mpuse, clone PY20; Santa Cruz, South 
San Francisco, CA) was diluted at 15 \i\ in 3 ml PBS containing 0.1% 
Tween-20 and 0.02% thermosal as preservative. 
Anti-phosphoserine antibody (rabbit, Zymed, South San Francisco, CA) 
was diluted at 6 |il in 3 ml PBS containing 0.1% Tween-20 and 0.02% 
thermosal as preservative. 
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Anti-phosphothreonine antibody (mouse, clone PT-5H5, Zymed, South 
San Francisco, CA) was diluted at 5 ^1 in 3 ml PBS containing 0.1% 
Tween-20 and 0.02% thermosal as preservative. 
Anti-c-fos antibody (100 \ig/m\, Ab-3, mouse, clone CS93.1.18; 
Calbiochem, Oncogene Research Products, Cambridge, MA) was 
diluted at 100 i^l in 3 ml PBS containing 0.1% Tween-20 and 0.02% 
thermosal as preservative. 
Anti-c-jun antibody (100 ^ig/ml, Ab-3, mouse, clone 76; Calbiochem, 
Oncogene Research Products, Cambridge, MA) was diluted at 100 i^l in 
3 ml PBS containing 0.1% Tween-20 and 0.02% thermosal as 
preservative. 
Anti-c-myc antibody (Ab-3, mouse, Oncogene Science) was diluted at 
20 ^1 in 3 ml PBS containing 0.1% Tween-20 and 0.02% thermosal as 
preservative. 
3.2 Methods 
3.2.1 Extraction and Characterization of Klebsiella 
pneumoniae K24 Capsular Polysaccharide (K24 CPS) 
3 2.1.1 Preparation ofKlebsiella pneumoniae K24 Capsular 
Polysaccharide (K24 CPS) 
The Klebsiella pneumoniae K24 Capsular Polysaccharide was prepared 
as modified from Choy et al (1973). Klebsiella pneumoniae K24 
bacteria was cultured on agar plate containing culture medium (2g NaCl , . 
lg K2HPO4, 0.25g MgS04.7H20, 0.5g CaCO3, 30g sucrose, 2g Bacto 
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Yeast Extract, 15g Bacto Agar per L H2O). The bacteria was harvested 
with 2% phenol in 0.85% saline and the bacteria suspension was diluted 
1.75 fold to 1.6L. The suspension was ultracentrifuged at 29000rpm for 
2.5h at 40C to separate the bacteria from the supernatant containing the 
K24 CPS. The supernatant was dialysed with dialysis tubing of 
molecular cut offof3500 Da in running water for 17 h. The supernatant 
was lyophilized for 3 days. The crude sample was weighed ( 4.7118g). 
1.7462 g crude sample was dissolved in 174.62 ml water (1% solution) 
and the remaining crude sample was kept as stock. K24 CPS in the 
solution was precipitated with 40 ml 5% Cetavlon Solution. The 
precipitate was centrifuged down at 2800g for 5 min. The supernatant 
was discarded and the pellet was dissolved in minimal volume of 4M 
NaCl. The solution was slowly added into 5-7 volume of 95% ethanol 
with continuous stirring. The precipitate was centrifuged down at 2800g 
for 5 min. The procedure was repeated twice. The precipitate was 
dissolved in 400 ml water. The solution was dialysed with dialysis 
tubing of molecular cut off of 3500 Da in distilled water for 17 h. The 
solution was lyophilized for 3 days. The purified sample was weighed 
(0.7473g). 
3.2.1.2 Acetic Acid Treatment of Klebsiella pneumoniae K24 
Capsular Polysaccharide 
19 mg purified K24 CPS was dissolved in 19 ml 2% acetic acid. The 
solution was boiled at 100OC for 90 min. to deacylate LPS if present. 
The precipitate was centrifuged down at 200 g for 5 min. to remove the 
lipid A ifpresent. The supernatant was dialysed with dialysis tubing of 
molecular cut offof3500 Da in distilled water for 17 h. The supernatant . 
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was lyophilized for 3 days. The acetic acid-treated sample was weighed 
(17mg). 
3 2.1.3 Gel Filtration 
K24 CPS was applied onto a Sepharose CL-2B (Pharmacia) column (2.6 
cm X 57 cm) and eluted with NaCl to obtain fractions. Fractions of4.95 
ml were collected at a flow rate of 19.8 ml/h. The relative amount of 
carbohydrate in each fraction was determined by the phenol-sulphuric 
acid method (Absorbance at 485 nm). 
3 2.1.4 Determination of Carbohydrate content 
Carbohydrate content of K24 CPS sample were determined by phenol-
sulphuric acid method (Dubois et al, 1956) and aborbance at 490nm was 
measured. 
3.2.1.5 Determination ofProtein content 
Protein content of K24 CPS sample were determined by BCA Protein 
Assay Reagent Kit (PIERCE, Rockford, USA.). 0.1 ml of each standard 
or unknown sample was pipetted into appropriately labelled test tube 
was measured. 2.0 ml of the working reagent which was prepared by 
mixing 50 parts ofBCA reagent A with 1 part ofBCA reagent B, was 
added to each tube and mixed well. All tubes were incubated at 37^0 for 
30 min. After incubation, all tubes were cooled to room temperature. 
The aborbance at 562 nm of each tube was measured. A standard curve _ 
was prepared by plotting the aborbance at 562 nm reading for each BSA 
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standard versus its concentration. Using the standard curve, the protein 
concentration for the K24 CPS sample were determined. 
3 2.1.6 Cytotoxicity Assay using Artemia franciscana (Brine 
Shrimp) 
The brine shrimp eggs was hatched in artificial sea water under 
illumination at 22-290Cfor 36h. Nauplii was counted in the stem ofthe 
pasteur pipette against a light background and 10 was transferred to each 
small glass vial. K24 CPS was dissolved in salt water and the 
concentrations of 1000，100, 10 i^gAnl was prepared. Hippuric Acid 
which was acted as positive control was dissolved in salt water and the 
concentrations of 500, 50, 5 i^g/ml was prepared. Artificial sea water 
was used as control. The shrimp was illuminated at TPC for 24h. The 
shrimps was removed from the vial to a 35 mm petri dish. The numbers 
of survivors and deaths was recorded respectively. The lethal 
concentration (LC50) was estimated using Reed-Muench Method. LC50 
is the concentration of test sample at which causes 50% oftotal shrimp 
deaths. Test compound ofLC50 greater than 1000 ^ig/ml is considered 
as non-toxic. 
3.2.2 Assays ofImmunomodulatory Activities ofK24 CPS on 
Lymphocytes 
3.2.2.1 in vitro Mitogenic Assay ofK24 CPS using Murine 
Splenocytes 
Three BALB/c mice were sacrificed and the spleens were removed and 
grinded with 4-5 ml 10 % FCS-RPMI per spleen. The spleen cells are 
centrifuged at 20 g for 20 s to remove the connective tissues. The _ 
supernatant was obtained and washed at 2000 rpm for 5 min. The pellet 
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was resuspended with 2 ml 10 % FCS-RPMI and cetrifuged at 2000 rpm 
for 5 min. The pellet was resuspended with 2 ml 10 % FCS-RPMI. Cell 
density was determined by trypan blue exclusion method. The cell 
density ofthe suspension was adjusted to 5 x 10^ cells/ml. 100 i^l cell 
suspension (5 x 10^ cells) was seeded in each well of flat-bottomed 96-
well microplate. Serial dilutions ofK24 CPS and Con A of lO i^g/ml 
were prepared. 100 i^l K24 CPS of different serial concentrations or 10 
o/o FCS-RPMI as control were added to the splenocyte-containing wells 
to make up the well volume to 200 i^l. The plate was incubated at 370C 
humidified 5% CO2 for 48 h. 
Six h prior to the end of incubation, the cells were pulsed with 50 i^l 10 
^Ci/ml 3H-thymidine (0.5^iCi) per well. The plate was subjected to one 
cycle offreezing and thawing to lyse the cells. The cells were harvested 
onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of 3H-thymidine into DNA of the 
splenocytes was determined by a liquid scintillation counter. The data 
were expressed as mean counts per min., (CPM) 士 S.D. The Stimulation 
Index (S.I.) is calculated as follows: 
S.I.= CPM ofthe treated group / CPM of the control group 
The graph ofS.I. was plotted against K24 CPS concentrations. 
3.2.2.2 in vivo Mitogenic Assay of K24 CPS on Murine Splenic 
Lymphocytes 
On day 0, BALB/c mice were divided in groups of eight and each 
injected i.p. with 50 i^g K24 CPS in 0.2ml PBS or, 0.2 ml PBS as 
control. 
On day 3，BALB/c mice of each group were sacrificed and weighed, and . 
the spleens were removed and weighed. The spleens were grinded with 
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4-5 ml 10 % FCS-RPMI per spleen. The spleen cells are centrifuged at 
500 rpm for 20 s to remove the connective tissues. The cell suspension 
of different groups were layered on the top of same volume of Ficoll-
paque and were centrifuged at 3000 rpm at 2QOC for 20 min. The 
lymphocytes at the interface ofthe two layers were drawn. The cells was 
washed with 1 ml at 2000 rpm for 5 min. The pellet was resuspended 
with 0.5 ml RPMI-10% FCS. The cell density was determined by trypan 
blue exclusion. The cell density was adjusted to 2.5xl06 cells/ml. 200 i^l 
cell suspension (5 x 10^ cells) was seeded in each well of flat-bottomed 
96-well microplate. 
The cells were pulsed with 50 i^l 10 ^Ci/ml 3H-thymidine (0.5 i^Ci) per 
well for 6 h. The plate was subjected to one cycle of freezing and 
thawing to lyse the cells. The cells were harvested onto a glass fibre 
filter with distilled water by a cell harvester. The glass fibre filter was 
dried. Incorporation of 3H-thymidine into DNA of the splenic 
lymphocytes was determined by a liquid scintillation counter. The data 
were expressed as mean counts per min., (CPM) 士 S.D. The Stimulation 
Index (S.I.) is calculated as follows: 
S.I.= CPM ofthe treated group / CPM of the control group 
3.2.2.3 Assay ofthe Effect ofK24 CPS on the Production of 
Interleukin-2 (IL-2) by Murine Splenocytes 
Day 0, Con A Blast Cells was prepared as follows. Three BALB/c mice 
were sacrificed and the spleens were removed and grinded with 4-5 ml 
10 % FCS-RPMI per spleen. The spleen cells were centrifuged at 500 
rpm for 20 s to remove the connective tissues. The supernatant was 
obtained and washed at 2000 rpm for 5 min. The pellet was resuspended 
with 2 ml 10 % FCS-RPMI and cetrifuged at 2000 rpm for 5 min. The . 
pellet was resuspended with 2 ml 10 % FCS-RPMI. Cell density was 
32 -
determined by trypan blue exclusion method. The cell density of the 
suspension was adjusted to 2 x 10^ cells/ml in RPMI-10% FCS 
containing 2.5^g/ml Con A. 4 ml cell suspension (8 x 10^ cells) was 
seeded in each well offlat-bottomed 6-well culture plate. The cells in 6-
well plate (PLATE 1) were incubated for 72 h at 37 oc in humidified 
5% CO2. 
On day 1, splenocytes from BALB/c mice were prepared as mentioned 
above. The cell density was adjusted to 5 x 10^ cells/ml in RPMI-10% 
FCS. lOO i^l cell suspension (5 x 10^ cells) was seeded to each well of 
flat-bottomed 96-well culture plate (PLATE 2). 100^d K24 CPS of 
different serial dilutions and Con A (lO^g/ml) were added to each well 
respectively 
The cells in the plate (PLATE 2). were cultured for 48 h at 37 ^C in 
humidified 5% CO2. 
On day 3, the culture (PLATE l)was examined for the presence ofCon 
A blast cells (large lymphoblasts). The cells was washed three times 
with RPMI-10% FCS. The large lymphocytes was separated by Ficoll-
paque gradient centrifugation. The cell density was adjusted to 5 x 10^ 
cells/ml in RPMI-10% FCS. lOO i^l Con A blast cell suspension (5 x 10^ 
cells) was seeded to each well. PLATE 2 was centrifuged at 400g for 5 
min. lOO i^l Splenocyte conditioned medium was transferred or IL-2 
Standards was added to the Con A blast cell containing wells. The cells 
were cultured for 18 h at 37 0C in humidified 5% CO2. The cells were 
pulsed with 50 i^l (10 ^iCi/ml) 3H-TdR (0.5 i^Ci) for 6 h at 37 oc in 
humidified 5% CO2. The plate was subjected to one cycle of freezing 
and thawing to lyse the cells. The cells were harvested onto a glass fibre 
filter with distilled water by a cell harvester. The glass fibre filter was 
dried. Incorporation of 3H-thymidine into DNA of the Con A blast cell 
was determined by a liquid scintillation counter. The data were 
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expressed as mean counts per min., (CPM) 士 S.D. The Stimulation 
Index (S.I.) is calculated as follows: 
S.I.= CPM ofthe treated group / CPM of the control group 
3.2.3 Assays ofImmunomodulatory Effect ofK24 CPS on 
Macrophages 
3 2.3.1 Assay o fm vitro Stimulation ofMacrophage Nitric 
Oxide (NO) Production by K24 CPS 
On day 1, 3 BALB/c mice was each injected i.p with 1ml 3% Brewer 
thioglycollate. On day 4, the mice were killed and the abdomen of each 
mice was wetted with 70% ethanol to sterilize the area. A midline 
incision was made with sterile scissors. The abdominal skin was 
retracted with forceps to expose the intact peritoneal wall. A 30-cc 
syringe was attached to 19-G needle and filled with HBSS. The syringe 
plunger was pushed to allow a small amount ofHBSS to pass through 
the needle as the needle penetrates the peritoneum to avoid hitting the 
intestines. With bevelled end of needle facing up, the needle was 
inserted through peritoneal wall at the midline. Each mouse was injected 
with 10ml HBSS. Using the same syringe and needle, the needle was 
inserted into the peritoneum with the bevelled end of the needle facing 
down. The needle was slightly raised to causing tenting ofthe peritoneal 
wall. The peritoneal fluid was slowly withdrawn. The needle was 
removed from the syringe and the peritoneal fluid was dispensed to 50-
ml centrifuge tube on ice. The cells were centrifuged at 2000 rpm for 3 
min. Half-isotonic PBS was added to lyse the contaminating red blood 
cells. The cells was centrifuged at 2000 rpm for 3 min. The lysing 
process was repeated until most ofthe red blood cells were lysed. The 
cells were resuspended with 1ml RPMI-10% FCS. Cell density was -
determined by trypan blue exclusion method. The cell density of the 
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suspension was adjusted to 1 x 10^ cells/ml. 100 i^l cell suspension (1 x 
105 cells) was seeded to each well. The cells were incubated at 37 oC in 
humidified 5% CO2 for 4 h. The medium was aspirated from the wells 
& the wells were washed twice with warm RPMI-10% FCS. Two-fold 
serial dilutions of K24 CPS were prepared and 100 i^l K24 CPS at 
different serial dilutions was added to each well. The cells were 
incubated at 37^0 in humidified 5% CO2 for 24h. 
After incubation, 50^1 culture medium was transferred from each well to 
another flat-bottomed 96-well plate. Serial dilutions of sodium nitrite 
which was used as standard was prepared and 50 i^l of each 
concentration was also added to the well of the plate. 50 i^l Greiss 
Reagent (1 % sulphanilamide, 0.1 % naphthylethylenediamine 
dihydrochloride and 2.5% H3PO4) was added to the culture medium or 
sodium nitrite in the wells. The contents of the wells was mixed. The 
absorbance at 540 nm of each well was measured by microplate reader. 
The standard curve of plotting absorbance at 540 nm against sodium 
nitrite concentrations was constructed. The sodium nitrite concentration 
ofthe culture medium was found by using the standard curve. 
3.2.3.2 Assay ofiVi vitro Stimulation ofMacrophage Tumour 
Necrosis Factor- a (TNF-a) Production by K24 CPS 
On day 1, 3 BALB/c mice was each injected i.p with 1ml 3% Brewer 
thioglycollate. On day 4, the mice were killed and the abdomen of each 
mice was wetted with 70% ethanol to sterilize the area. A midline 
incision was made with sterile scissors. The abdomenal skin was 
retracted with forceps to expose the intact peritoneal wall. A 30-cc 
syringe was attached to 19-G needle and filled with HBSS. The syringe ' 
plunger was pushed to allow a small amount of HBSS to pass through 
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the needle as the needle penetrates the peritoneum to avoid hitting the 
intestines. With bevelled end of needle facing up, the needle was 
inserted through peritoneal wall at the midline. Each mouse was injected 
with 10ml HBSS. Using the same syringe and needle, the needle was 
inserted into the peritoneum with the bevelled end of the needle facing 
down. The needle was slightly raised to causing tenting ofthe peritoneal 
wall. The peritoneal fluid was slowly withdrawn. The needle was 
removed from the syringe and the peritoneal fluid was dispensed to 50-
ml centrifuge tube on ice. The cells was centrifuged at 2000 rpm for 3 
min. Half-isotonic PBS was added to lyse the contaminating red blood 
cells. The cells was centrifuged at 2000 rpm for 3 min. The lysing 
process was repeated until most ofthe red blood cells were lysed. The 
cells were resuspended with 1ml RPMI-10% FCS. Cell density was 
determined by trypan blue exclusion method. The cell density of the 
suspension was adjusted to 1 x 10^ cells/ml. 100 i^l cell suspension (1 x 
105 cells) was seeded per well. The cells were incubated at 37^0 in 
humidified 5% CO2 for 4 h. The medium was aspirated from the wells 
& the wells were washed twice with warm RPMMO%FCS. Two-fold 
serial dilutions of K24 CPS were prepared and 100 i^l K24 CPS at 
different serial dilutions was added to each well. The cells were 
incubated at 370C humidified 5% CO2 for 24h.l00 i^l L929 (3 x 104 
cells) cell suspension in RPMI-10%FCS was seeded per well into 
another plate (L929 plate) & incubate at 37^0 in humidified 5% CO2 
for 24 h. On day 5, culture medium was aspirated from the wells ofthe 
L929 plate. 50 |il Actinomycin-D (4 ^ig/ml)-RPMI-5% FCS was added. 
50 i^l macrophage-conditioned medium was transferred from the 
macrophage plate to each well of the L929 plate. 50 i^l RPMI-5%FCS 
was added to each well of control. The total well volume was 100 ^d. 
The cells was incubated at 37^C in humidified 5% CO2 for 24 h. On 
day 6, the medium from L929 plate was gently discarded and the wells 
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were washed twice with warm PBS. 50 i^l 0.5% Neutral Red was added 
to each well and the plate was incubated for lh. The cells in the plate 
was incubated at 37^0 humidified 5% CO2 for 1 h. The wells were 
washed twice with warm PBS and the plate was dried in oven. lOO i^l 1% 
SDS was added to each well for cell lysis. Absorbance at 540 nm of 
each well was read by microplate reader using 1% SDS as blank. 
3.2.3.3 Assay ofin vitro Stimulation ofMacrophage 
Interleukin-1 (IL-1) Production by K24 CPS 
On day 1，3 BALB/c mice was each injected i.p with 1ml 3% Brewer 
thioglycollate. On day 4，the mice were killed and the abdomen ofeach 
mice was wetted with 70% ethanol to sterilize the area. A midline 
incision was made with sterile scissors. The abdominal skin was 
retracted with forceps to expose the intact peritoneal wall. A 30-cc 
syringe was attached to 19-G needle and filled with HBSS. The syringe 
plunger was pushed to allow a small amount of HBSS to pass through 
the needle as the needle penetrates the peritoneum to avoid hitting the 
intestines. With bevelled end of needle facing up, the needle was 
inserted through peritoneal wall at the midline. Each mouse was injected 
with 10ml HBSS. Using the same syringe and needle, the needle was 
inserted into the peritoneum with the bevelled end of the needle facing 
down. The needle was slightly raised to causing tenting ofthe peritoneal 
wall. The peritoneal fluid was slowly withdrawn. The needle was 
removed from the syringe and the peritoneal fluid was dispensed to 50-
ml centrifuge tube on ice. The cells was centrifuged at 2000 rpm for 3 
min. Half-isotonic PBS was added to lyse the contaminating red blood 
cells. The cells was centrifuged at 2000 rpm for 3 min. The lysing 
process was repeated until most of the red blood cells were lysed. The -
cells were resuspended with 1ml RPMMO% FCS. Cell density was 
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determined by trypan blue exclusion method. The cell density of the 
suspension was adjusted to 5 x 10^ cells/ml. 100 i^l cell suspension (5 x 
105 cells) was seeded per well. The cells were incubated at 37^0 in 
humidified 5% CO2 for 4 h. The medium was aspirated from the wells 
& the wells were washed twice with warm RPMI-10%FCS. Two-fold 
serial dilutions of K24 CPS were prepared and 100 ^1 K24 CPS at 
different serial dilutions was added to each well. The cells were 
incubated at 37^0 humidified 5% CO2 for 24h. 
On day 5，thymocytes were extracted from BALB/c mice similar to that 
in splenocyte extraction. Cell density was adjusted to 1 x 10? cells/ml. 
100 i^l (1 X 106 cells) cell suspension was seeded per well. 50|il IL-2 广 
(40U/ml) in RPMI-10%FCS was added to each well. 50 ^1 macrophage-
conditioned medium was transferred from to each well and 50^1 RPMI-
10%FCS was added to each well of the control group. The cells were 
incubated at 37^0 humidified 5% CO2 for 72h. 
Six h prior to the end of incubation, the cells were pulsed with 50 i^l 10 
|iCiAnl 3H-thymidine (0.5^iCi) per well. The plate was subjected to one 
cycle offreezing and thawing to lyse the cells. The cells were harvested 
onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of ^H-thymidine into DNA of the 
splenocytes was determined by a liquid scintillation counter. 
3.2.3.4 Assay ofin vivo Migration ofMacrophage by K24 CPS 
The method described by Gervais et al (1984) was followed with minor 
modification. On day 0，BALB/c mice in group of four were either 
injected i.p. with 50 i^g K24 CPS in 0.2 ml PBS or 0.2 ml PBS. On day " 
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3, peritoneal exudate cells of individual mouse was harvested and 
counted. 
3.2.4 Assays ofAnti-Tumour Activities ofK24 CPS 
3 2.4.1 Assay ofIn vitro Suppression ofEAT growth by K24 
CPS 
EAT cells were harvested from continuous culture. The cells were 
washed with PBS and were centrifuged at 2000 rpm for 3 min. The 
pellet was resuspended with RPMI and was centrifuged at 2000 rpm for 
3 min. The cells was then resuspended with 10% FCS-RPMI. The cell 
density was determined by trypan blue exclusion method. The cell 
density was adjusted to lxl05 cells/ml. lOO i^l cell suspension (lxl04 
cells) was seeded in each wells of a flat-bottomed 96-well plate. lOO t^l 
K24 CPS / LPS / Dextran at different 2-fold serial dilutions was added 
to the EAT cell-containing wells. The cells were incubated at 370C in 
humidified 5% CO2 for 2 days. 0.5jiCi ^H-TdR (50^il) was added to 
each well 6h prior to the end of incubation. The cells were then 
subjected to one cycle offreezing and thawing. The cells were harvested 
onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of ^H-thymidine into DNA of the 
EAT cells was determined by a liquid scintillation counter. The data 
were expressed as mean counts per min.(CPM) 士 S.D. The % 
Suppression was calculate as follows: 
% Suppression = [(CPMcontrol"CPMK24 CPSVCPMcontrol] x 
100% � 
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where CPMcontrol is the mean count per minute of the control 
group and CPMK24 CPS is the mean count per minute of the K24 CPS-
treated group. 
The graph of % Suppression was plotted against K24 CPS 
concentrations. 
3.2.4.2 The effect ofK24 CPS on cell cycle ofEAT cells 
1 X 105 EAT were co-cultured 200 i^g/ml K24 CPS or 10 %-FCS RPMI 
medium in the wells of24-well plate. After 48-h incubation, the cultured 
cells were fixed with 70% ethanol at 4^0 for 24 h. The cells were then 
stained with propidium iodide at room temperature for 30min. The cell 
cycle pattem of the cells was determined by FACSORT flow 
cytommeter. 
3.2.4.3 Study ofthe cytostatic effect ofK24 CPS on EAT cells 
using Western Analysis 
Protein sample preparation ofEAT cells 
EAT cells ( 3 X 1 0 5 ) were cultured in 3 ml complete RPMI medium in the 
presence or absence of K24 CPS for 1 or 2 days. At appropriate time, 
cells were first washed three times with 3 ml PBS containing lmM 
meta-Vanadate and centrifuged at 14000 rpm at 4�C for 5 min. The cells 
were lysed in 50 i^l lysis buffer (1% Triton-X100-21^ig/ml aprotinin-
lmM phenylmethylsulphonyl fluoride- 0.5^ig/ml leupeptin-4.9mM 
MgCl2-lmM vanvdate in PBS) in 1.5ml microcentrifuge tubes and 
centrifuged at 14000 rpm at 4°C for 5 min. After centrifugation, protein 
content in the supernatant was quantitated using the Micro BCA Protein 
Assay Kit (Pierce Chemical Co., Rockford, IL). The volume of the 
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supernatant was measured and transferred to a screw-cap 
microcentrifuge tube. The supernatant was diluted with 2X sodium 
dodecyl sulphate sample buffer (125 mM Tris-2.2 M glycerol-1.42 M p-
mercaptoethanol-160 mM sodium dodecyl sulphate-10 mg/L 
bromophenol blue, pH 6.8), boiled for 10 min and stored at -7QOC until 
use. 
SDS-polyacrylamide gel electrophoresis ofprotein 
The gel box was set up using 1 mm spacers according to instruction. 
Lower gel of 8% (for protein size 49 to 194 kDa) or 12% (for protein 
size 21.9 to 142.9 kDa) acrylamide lower gel solution was made 
according to the following table: 
Amount needed for 2 small sels 8% 12% 
Double-distilled Water 7.63 ml 5.5 ml 
30% Acrylamide 
(Sigma Chemical Co., St. Louis, MO) 4.27 ml 6.4 ml 
4X Lower Gel Buffer 4 ml 4 ml 
TEMED (Gibco, USA) 18.6 i^l 18.6 ^ il 
10% Ammonium Persulphate 80 i^l 80 ^ il 
(Sigma Chemical Co., St. Louis, MO) 
Total Volume (-5ml/gel) 15.9986ml 15.9986ml 
Gel solution was pour to 2.2 cm from top of glass with a 5 ml pipette. 
The top was immediately overlayed with a few millimeters of water-
saturated iso-butanol and allowed to set for at least for 1 hr. 
4.5% Acrylamide upper stacking gel was made as follows: 
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4mnunt needpd fnr 2 small 2els ^ ^ ^ 一 
Double-distilledWater • ^'；^ 
30% acrylamide (Sigma Chemical Co., St. Louis, MO) 1.2 ml 
4XUpper gelbuffer 2八0,1 
TEMED (Gibco, USA) 丄^？丄 
10% Ammonium Persulphate 60 \ii 
(Sigma Chemical Co., St. Louis, MO) 
;^:^;^^I^rV^I^I^i^^ ^ 8.07 ml 
Iso-butanol was poured off and washed twice with double-distilled 
water, and remaining water was removed by kimwipes. Gel was poured 
to top oflower gel with a pasteur pipette to avoid bubbles formation. 15-
well combs was inserted. The gel was allowed to set for 30 min. The gel 
chamber was assembled according to manufacturer's instruction. Upper 
reservoir was filled with about 115 ml and lower reservoir with 200 ml 
IX SDS Running Buffer. The combs was carefully removed. 
Sample Loading and Gel Running 
The protein concentration of sample was adjusted to 25^ig protein in 15 
^1 with IX Sample Buffer. 5 i^l Prestained Molecular Weight Standards 
(Bio-Rad) in lO i^l IX Sample Buffer or 15 t^l sample was loaded to each 
well. Gels were run at constant voltage of200V for 30 min. 
Electroblotting 
Thick blotter papers (Bio-Rad) and Immobilon-P membranes (Millipore, 
Bedford, MA) of size similar to that of the gel were cut. Immobilon-P 
membrane was wet for 1-2 sec in 100% methanol in square petri dish 
and placed in E-blot Transfer Buffer for 5 min. After running, the gels 
were rinsed in E-blot Transfer Buffer once. One piece of blotter paper 
was soaked in E-blot Transfer Buffer and placed onto the platinum 
anode ofthe semi-dry transfer unit (Bio-Rad). The surface of the blotter ' 
paper was rolled over by a test tube to exclude all air bubbles. 
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The equilibrated membrane was carefully placed on the blotter paper 
and rolled out air bubbles. The gel was placed on the top of the 
membrane with orientation same as the gel when loading (i.e. first lane 
at the left hand side) and rolled out all air bubbles. One piece ofblotter 
paper was soaked in E-blot Transfer Buffer and place onto the gel and 
rolled out all air bubbles. The same steps were repeated for other gels. 
The cathode was careMly placed onto the stack, then the safety cover 
was placed. The transfer was carried for 30 min at 15V, limited to 0.5A 
for 1 to 2 gels, lA for 4 gels. The membrane was removed from semi-
dry transfer unit (Bio-Rad) and the membrane was air dried at room 
temperature. The membrane was kept between two pieces ofclean paper 
or in an envelope for later use, or directly used for antibody probing and 
blot developing. 
Antibody Probing 
The membranes were immersed in methanol of 10 sec then into IX PBS 
for 2 s. The membranes were incubated in 5% non-fat dry milk at 4°C 
overnight for blocking the membranes. The membrane were rinsed three 
times with PBS containing 0.1% Tween 20 (PBS-T). The membranes 
were rocked in PBS-T for 10 min and the PBS-T was drained. Rinsing 
and draining was repeated once. Primary antibody was diluted in PBS-T, 
and lO i^l of 10% thimerosal was added as preservative for every 3 ml 
PBS-T containing primary antibody. The primary antibody was added to 
the membrane and rocked in a square pert dish for 2 hr at room 
temperature. The membrane was rocked by hand about every 30 min to 
prevent the membrane stick to the bottom of the dish. (The used diluted 
primary Ab can be stored at 4�C in a tube and reused later for 1-2 more 
times.) The membranes were rinsed three times with PBS-T. The 
membranes were rocked in PBS-T for 10 min and the PBS-T was 
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drained. Rinsing and draining was repeated once. Horseradish 
peroxidase-conjugated secondary antibody-sheep anti-mouse IgG 
(Amersham, Arlington Heights, IL) or donkey anti-rabbit IgG 
(Amersham, Arlington Heights, IL), depending on the origin of the 
primary antibody, was diluted at 1:20000 (0.25 i^l Ab/5 ml PBS-T) in 
PBS-T. Each membrane was rocked in 5 ml diluted secondary antibody 
for 1 h at room temperature. The membrane was rinse three times with 
PBS-T. The membranes were rocked in PBS-T for 10 min and the PBS-
T was drained. Rinsing and draining was repeated once. The membrane 
was ready for detection using ECL Chemiluminescence System 
(Amersham Arlington Heights, IL). 
Detection (by ECL Western Blotting Detection Reagents, 
Amersham) 
Equal volumes ofdetection reagents 1 & 2 ofthe ECL reagent kit were 
mixed (4 ml reagent mixture for each membrane). Each membrane was 
placed on a square petri dish with protein side up. The detection reagent 
mixture was added to the protein side of the membrane so that the 
reagent was held by surface tension on the surface of the membrane. 
The membrane was incubated exactly 1 min at room temperature 
without agitation. Excess detection reagent was drained off by only 
holding the edge of the membrane vertically against tissue paper. The 
membrane was placed on a saran-wrap with protein side down and 
wrapped on the back. Any air pockets were gently smoothed out. The 
membrane was placed with protein side up in the film cassette. In dark 
room, a sheet of autoradiography film (X-AR film, Kodak) was 
carefully placed on top of the membranes, the cassette was closed and 
exposed for 15 sec to 1 min. The exposed film was removed and 
developed in an automatic film processor. A unexposed film was 
immediately replaced and expose for about 5 min. 
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3.2.4.4 Assay ofIn vivo Suppression ofEAT growth by K24 
CPS 
BALB/c mice were divided in groups of five and each injected i.p. with 
K24 CPS, LPS or PBS as control according to different regimens. 
[ D ^ |RegimenA |RegimenB |RegimenC 
,2 -1 0 1 2 2QugK24 CPS orLPS 20^gK24 CPS orLPS 
， ， ， ， /0.2mlPBS/ /0.2mlPBS/ 
mouse/day mouse/day 
0 10^> EAT cells/ 10^ EATcells/ 10^ EATcells/ 
0 2ml PBS/mouse 0.2ml PBS/mouse 0.2ml PBS/mouse 
"" 25^igK24 CPS or 
LPS 
~ ~ 1 re11 Harvestin. 一 /0.2ml PBS/ mouse/day 
9 Cell Harvesting Cell Harvesting 
For the control group of each regimen, 0.2 ml PBS was injected i.p. to 
each mouse of the group. After regimen, the peritoneal cells were 
harvested from the peritoneal cavity of each mouse of each group with 
25 ml PBS. The cell suspension was centrifuged at 2000 rpm for 5 min. 
The pellet was resuspended with 10 ml PBS. The cell suspension was 
dilute 10-folded. The cell number was determined by trypan exclusion 
method. The % Suppression ofeach group was calculate as follows: 
% Suppression=[GSfcontrol- NK24 CPS/LPS-treated group)^controll x 
100% 
where Ncontrol is the mean number ofEAT cells present in the 
peritoneal cavity ofthe mice of the control group and 
NK24 CPS is the mean number ofEAT cells present in the 
peritoneal cavity ofthe mice ofthe K24 CPS-treated group . 
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3,2.4.5 Assay ofIn vivo induction ofTNF -a production by K24 
CPS 
TNF-a-containing serum (TNS) was prepared as follows. K24 CPS and 
LPS of different concentrations were prepared. ICR mice were divided 
into groups of four. Each mouse of each group was injected with 0.2ml 
of different concentrations of K24 CPS or LPS. After 1.5h, blood was 
collected from each mouse by cardiac puncture using 25G needle with 
syringe. The blood was clotted ovemight and then centrifuged at 4000 
rpm for 10 min. The supernatant which was the serum was obtained. 
The serum was diluted with equal volume of plain RPMI. The diluted 
serum was heated at 560C for 30 min to destroy the complement system 
and filtered by Millipore 0.22^im disposable filter. The serum was stored 
at -20^C before use. 
Serum TNF-a Assay using L929cells was performed. On Day 1, 100 ^1 
L929 cell suspension in RPMI-10%FCS (3 x 104 cells) was seeded per 
well ofthe flat-bottomed 96-well plate (L929 plate) and the cells were 
incubated at 370C in humidified 5% CO2 for 24h. On day 2, the TNS 
was 2-fold serially diluted with plain RPMI. The medium was aspirated 
from each wells ofthe L929 plate. 50 i^l TNS ofdifferent concentrations 
in plain RPMI or 50 i^l plain RPMI (as control) were added to the L929 
cell-coated wells. 50^1 Actinomycin-D (4 ^g/ml)-RPMI-10 %FCS was 
added to each well to make the total well volume to lOO i^l. The cells 
were incubated at 370C in humidified 5% CO2 for 24h. On day 6, the 
medium from L929 plate was gently discarded and the wells were 
washed twice with warm PBS. 50 i^l 0.5% Neutral Red was added to 
each well and the plate was incubated for lh. The cells in the plate was 
incubated at 370C in humidified 5% CO2 for 1 h. The wells were 
washed twice with warm PBS and the plate was dried in oven. lOO i^l 1% 
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SDS added to each well for cell lysis. Absorbance at 540 nm of each 
well was read by microplate reader using 1% SDS as blank. 
3 2.4.6 Assay ofin vivo Effect ofK24 CPS and LPS on the 
Endogenous TNF-a Production and the Suppression ofEAT in 
EAT-Bearing Mice 
On day 0, ICR mice were divided in groups of ten (K24 CPS group, LPS 
group and control group). Each mice was inoculated with 1 x 10^ EAT 
cells in 0.2 ml PBS. 
On day 6, each mouse ofK24 CPS group, LPS group and control group 
was injected i.v. with lO^g K24 CPS in 0.2 ml PBS, 10 i^g LPS in 0.2 
ml PBS and 0.2 ml PBS respectively. After 1.5h, blood was collected 
from 5 mice of each group by cardiac puncture using 25G needle with 
syringe. The blood was clotted ovemight and then centrifuged at 4000 
rpm for 10 min. The supernatant which was the serum was obtained. 
The serum was diluted with equal volume of plain RPMI. The diluted 
serum was heated at 560C for 30 min to destroy the complement system 
and filtered by Millipore 0.22^m disposable filter. The serum was stored 
at -20OC before use. Serum TNF-a Assay using L929cells was 
performed as described in the In vivo induction ofTNF-a production 
by K24 CPS. 
On day 7, the peritoneal cells were harvested from the peritoneal cavity 
of each ofthe other five mice of each group with 30 ml PBS. The cell 
suspension was centrifoged at 2000 rpm for 5 min. The pellet was 
resuspended with 20 ml PBS. The cell suspension was diluted 10-fold. 
The cell number was determined by trypan exclusion method. The % 
Suppression ofeach group was calculate as follows: 
47 -
% Suppression=[CNcontrol- ^K24 CPS/LPS-treated group)^control] x 
100% 
where Ncontrol is the mean number ofEAT cells present in the 
peritoneal cavity of the mice of the control group and 
NK24 CPS/LPS is the mean number ofEAT cells present in the 
peritoneal cavity ofthe mice ofthe K24 CPS/LPS-treated 
group. 
3.2.4.7 Assay ofthe Effect of K24 CPS on the Survival of 
EAT-bearing Mice 
BALB/c mice were divided in groups of twenty and each injected i.p. 
with K24 CPS or, PBS as control according to following regimen. 
Day K24 CPS-treated group — Control group 
-1,-2, 0, 1,2""^20p,g K24 CPS/0.2mlPBS/~""0.2mlPBS/ ‘ 
mouse/day mouse/day 
~6 """10^ EAT cells/ 10^ EAT cells/ 
0.2ml PBS/mouse Q.2ml PBS/mouse 
The number of deaths of each group was recorded on each day. The 
mean survival time of each group and the mortality pattem ofthe EAT-
bearing mice was determined. 
3.2.4.8 Assay ofin vitro Induction of Lymphokine-activated 
Killer (LAK) Cell by K24 CPS 
On day 1, 6 mice were killed. The spleens was grinded through the sieve 
with a syringe plunger. The cell extract was centrifuged twice at 500 
rpm for 20s to remove the connective tissue. The supernatant was 
centrifuged at 2000 rpm for 5 min. The pellet was resuspended in 6 ml 
RPMI-10% FCS. The cell density was determined by trypan blue 
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exclusion. The cell density was adjusted to 8 x 10^ cells/ml. The 
followings were prepared in a 6-well plate: 
Groups AVells [ ^ K24 CPS IL-2 |RPMI-
suspension (4Q0^ig/ml) (lOQQOU/ml) 10%FCS 
1. Spleen Cells (SC) 2ml 一 - 二 二 ^ 
2. SC+K24 CPS (5Q^ig/ml) 2ml 0.5ml - 1.5ml 
3. SC+IL-2 (5QU/ml) 2ml -- 20|il 1.98ml 
4.SC+K24~~^~~(50^ig/ml) 2ml 0.5ml 20^il 1.48ml 
+IL-2 (5QU/ml) 
5. SC+K24 CPS (50^ig/ml) 2ml 0.5ml 40^il 1.46ml 
+IL-2 (lOOU/ml) I 
The cells were incubated at 37^0 in 5% CO2 for 3 days(Day 0-3). 
On day 4, WEHI-164 Cells were seeded in the wells of a flat-bottomed 
96-well plate. The cells were harvested from continuous culture by 
centrifugation at 1500 rpm for 5 min. The cell density was determined 
by trypan blue exclusion. The cell density was adjusted to 4 x 10^ 
cells/ml. lOOp-l cell suspension(4 x 10^ cells) was seeded per well The 
cells was incubated at 37^0 in 5% CO2 for 24h. 
On day 5, LAK Cytotoxicity Assay was performed. The fresh spleen 
cells ofmice were extracted as described above. The cultured cells from 
wells 1-5 (Groups 1-5) of the 6-well plate were scrapped. The cell 
suspension of different groups were layered on the top of same volume 
ofFicoll-paque and were centrifuged at 3000 rpm at 2QOC for 20 min. 
The lymphocytes at the interface of the two layers were drawn. The cells 
was washed with 1 ml at 2000 rpm for 5 min. The pellet was 
resuspended with 0.5 ml RPMI-10% FCS. The cell density was 
determined by trypan blue exclusion. The cell density was adjusted to 
107 cells/ml. 100|il cell suspension was added to each well coated with ‘ 
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4 X 104 WEHM64 cells to make up the total well volume to 200jil. The 
cells was incubated at 37 0C in 5% CO2 for 24 h. 
On day 6, Neutral Red Uptake Assay was performed. The medium was 
discarded from the wells of the 96-well plate. The wells was washed 
twice with warm PBS. 50 i^l 0.25% neutral red was added to each well. 
The plate was incubated at 37^0 for 45 min. The wells was washed 
twice with warm PBS. The plate dried overnight in oven. lOO i^l 1% SDS 
was added per well. The absorbance at 540 nm of each well was 
measured by microplate reader. 100 i^l SDS was acted as blank. The 
cytotoxicity ofeach group of spleen cells was calculated as follows: 
% cytotoxicity=(C-T)/C x 100% 
where C = mean ofthe absorbance at 540nm of the control wells 
(no effectors) 
where T = mean ofthe absorbance at 540 nm of the treated wells 
(with effectors) 
3 2.4.9 Assay ofiVi vivo Induction ofActivity ofLymphokine-
activated Killer (LAK) Cells by K24 CPS 
On day 1 to 7, 6 BALB/c mice were injected with K24 CPS (50^ig/0.2 
ml PBS/mouse/day) (Group A). On day 4 to 10，2 BALB/c mice injected 
with K24 CPS (50^ig/0.2 ml PBS/mouse/day) (Group B). 
On day 8，splenocytes from K24 CPS-treated mice of Group A were 
cultured in different conditions as follows. The 6 mice of Group A were 
killed. The spleens were grinded through the sieve with a syringe 
plunger. The cell extract was centrifuged twice at 500 rpm for 20s to 
remove the connective tissue. The supernatant was centrifuged at 2000 
rpm for 5 min. The pellet was resuspended in 6 ml RPMI-10% FCS. The 
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cell density was determined by trypan blue exclusion. The cell density 
was adjusted to 8 x 10? cells/ml. The followings were prepared in a 6-
well plate: 
Groups /Wells [ ^ [ ^ CPS IL-2 |RPMI-
suspension (400^g/ml) (lOOOOU/ml) 10% 
FCS 
LSpleen Cells (SC) 2ml -- __ 2ml 
2. SC+K24 CPS (50^g/ml)~~ 2ml 0.5ml - 1.5ml 
3.SC+IL-2(5QU/ml) 2ml -- ^ ^ 1 1.98ml 
4. SC+K24 CPS (50^g/ml) 2ml 0.5ml 20^il 1.48ml 
+IL-2 (5QU/ml) _ | 
The cells were incubated at 37^0 in 5% CO2 for 3 days (Day 8-11). 
On day 10，WEHI-164 Cells were seeded in the wells of a flat-bottomed 
96-well plate. The cells harvested from continuous culture at 1500rpm 
for 5 min. The cell density was determined by trypan blue exclusion. 
The cell density was adjusted to 4 x 10^ cells/ml. lOO i^l cell 
suspension(4 x 10^ cells) was seeded per well The cells was incubated 
at 370c in 5% CO2 for 24h. On day 11, LAK Cytotoxicity Assay was 
performed. The spleen cells of mice of Group B (Group 5) and Normal 
Mouse (Group 6) were extracted as described above. The cultured cells 
from wells 1-5 (Groups l-5> of the 6-well plate were scrapped. The cell 
suspension of different groups were layered on the top of same volume 
of Ficoll-paque and were centrifuged at 3000rpm at 20^C for 20 min. 
The lymphocytes at the interface of the two layers were drawn. The cells 
was washed with 1 ml at 2000rpm for 5min. The pellet was resuspended 
with 0.5ml RPMI-10% FCS. The cell density was determined by trypan 
blue exclusion. The cell density was adjusted to lO^cells/ml. lOO i^l cell 
suspension was added to each well coated with 4 x 10^ WEHI-164 cells “ 
to make up the total well volume to 200^il. The cells were incubated at 
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370C in 5% CO2 for 24 h. On day 12, Neutral Red Uptake Assay was 
performed. The medium was discarded from the wells of the 96-well 
plate. The wells were washed twice with warm PBS. 50jil 0.25% neutral 
red was added to each well. The plate was incubated at 37^0 for 45 min. 
The wells were washed twice with warm PBS. The plate was dried 
ovemight in oven. 100^1 1% SDS was added to each well. The 
absorbance at 540nm of each well was measured by microplate 
reader.lOO i^l SDS was acted as blank. The cytotoxicity of each group of 
spleen cells was calculated as follows: 
% cytotoxicity=(C-T)/C x 100% 
where C=mean ofthe absorbance at 540nm of the control wells 
(no effectors) 
where T=mean ofthe absorbance at 540nm of the treated wells 
(with effectors) 
3.2.4.10 Natural Killer (NK) cell Cyotoxicity Assay 
Optimization oftarget cell number for use in the 
CytoTox96 Assay 
An aliquot ofYAC-1 cells was removed from continuous culture and 
centrifuged at 150 x g (3000 rpm) for 10 min. The cell pellet was 
washed with 2ml phenol red-free PRMI (PR-free RPMI) at 3000 rpm for 
10 min. The cells were resuspended in 1.5 ml PR-free RPMI. The cell 
concentration was determined by the trypan blue exclusion method. The 
cell suspension was diluted to 20 x 10^ cells/ml. Serial dilutions of the 
cell suspension in well volume of 100|il(x lO^ )： 20, 10，5, 2.5, 1.25, 
0.625, and 0 (culture medium control) and a quadruplicate set of wells 
were prepared for each cell concentration. 10 i^l lysis solution (10 x) 
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was added to all wells. The cells was incubated at 370C, 5% CO2 for 45 
min. The microplate was centrifuged at 250 x g for 4 min. 50 ^1 aliquots 
from all wells were transferred to the enzymatic assay plate (flat-
bottomed 96-well plate). 50 i^l substrate mix was added to each well of 
the enzymatic assay plate. The microplate was incubated at room 
temperature for 30 min. in the dark. 50 i^l stop solution was added to 
each wells. The contents of the wells were mixed at the microplate 
reader and large bubbles are removed by puncture using a hot syringe 
needle. The absorbance at 490nm was recorded and a mixture of 50 ^1 
distilled water, 50 i^l substrate mix and 50 i^l stop solution was used as 
blank. The concentration of target cells yielding absorbance values at 
least two times the background absorbance of the medium control was 
determined. 
Preparation ofEffector Cells 
On day 0，K24 CPS (lO^ig in 0.2ml PBS) were intravenously (i.v.) 
injected into BALB/c mice in group of three and 0.2ml PBS was 
injected instead for control group. On day 1, BALB/c mice were 
sacrificed and the spleens were removed and grinded with 4ml RPMI. 
The spleen cells were centrifuged at 500rpm for 20s (for removing the 
connective tissues). The supernatant was removed, layered on the top of 
4ml Ficoll and centrifuged at 3000rpm for 20 mins. The middle buffy 
layer of natural killer cell was obtained, washed and centrifuged at 
2000rpm for 5min. The pellet was resuspended with 0.5 ml RPMI. Cell 
concentration was determined by trypan blue exclusion method. The cell 
suspension was diluted to 1.25 x 10^ cells/ml. 50|il cell suspension 
(6.25 X 105 cells) was seated in each well of the cytotoxicity assay plate -
(round-bottomed 96-well plate). 
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Cytotoxicity Assay was carried out according to the procedure provided 
by Promega CytoTox-96 Assay. 
3.2.5 Assays of the Effects of K24 CPS on the Proliferation 
and Differentiation ofMurine Bone Marrow Cells 
3.2.5.1 Assay of the Proliferation ofMurine Bone Marrow 
Cells 
The murine bone marrow cells were prepared from BALB/c mice. Three 
BALB/c mice were killed by cervical dislocation. The femurs were 
removed and put into a petri dish containing cold 10% FCS-RPMI. The 
marrow plugs were flushed with 2ml 10% FCS-RPMI using a 25G 
needle with 2ml syringe. The bone marrow cells were separated from 
red blood cells by Ficoll-paque gradient centrifugation at 3000rpm for 
20 min. The bone marrow cells were washed twice with 10% FCS-
RPMI. 
The Proliferation Assay was performed. The murine bone marrow cells 
were resuspended in 10% FCS-RPMI and the cell density was adjusted 
to 106 cells/ml. Serial dilutions ofK24 CPS and Murine Interleukin-3 
(mIL-3) were prepared. 100 i^l cell suspension (105 cells) was seeded in 
each well offlat-bottomed 96-well microplate. 100 i^l K24 CPS or mIL-
3 of different serial concentrations or 10 % FCS-RPMI as control were 
added to the bone marrow cells-containing wells to make up each well 
volume to 200 ^1. The plate was incubated at 37^0 in humidified 5% 
CO2 for 72 h. Then, the cells were labelled with 50 i^l 10 ^iCi/ml ^H-
thymidine (0.5^iCi) per well for 24h. The plate was subjected to one 
cycle of freezing and thawing to lyse the cells. The cells were harvested 
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onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of ^H-thymidine into DNA of the 
bone marrow cells was determined by a liquid scintillation counter. The 
data were expressed as mean counts per min.(CPM) 士 S.D. The 
Stimulation Index (S.I.) is calculated as follows: 
S.L= CPM ofthe treated group / CPM of the control group 
The graph of S.I. was plotted against K24 CPS concentrations. 
3.2.5.2 Assay ofthe Differentiation ofMurine Bone Marrow 
Cells 
The murine bone marrow cells were prepared from BALB/c mice. Three 
BALB/c mice were killed by cervical dislocation. The femurs were 
removed and put into a petri dish containing cold 10% FCS-RPMI. The 
marrow plugs were flushed with 2ml 10% FCS-RPMI using a 25G 
needle with 2ml syringe. The bone marrow cells were separated from 
red blood cells by Ficoll-paque gradient centrifugation at 3000rpm for 
20 min. The bone marrow cells were washed twice with 10% FCS-
RPMI. 
The Differentiation Assay was performed. The murine bone marrow 
cells were resuspended in 10% FCS-RPMI and the cell density was 
adjusted to 10^ cells/ml. Serial dilutions of K24 CPS and Murine 
Interleukin-3 (mIL-3) were prepared. 100 ^1 cell suspension (10^ cells) 
was seeded in each well of flat-bottomed 96-well microplate. 100 ^1 
K24 CPS or mIL-3 ofdifferent serial concentrations or 10 % FCS-RPMI 
as control were added to the bone marrow cells-containing wells to 
make up the well volume to 200 i^l. The plate was incubated at 37^C in 
humidified 5% CO2 for 72 h. lOO i^l cell suspension was taken from ‘ 
each well and the cells were fixed on a slide by cytospin at 500rpm for 5 
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min. The fixed cells were stained with the Hemacolar® Rapid Blood 
Smear Staining set by Merck. The fixed cells on the slide were 
immersed five times for one second each time into solution 1 and the 
solution was allowed to drip off. Then the fixed cells on the slide were 
immersed three times for one second each time into solution 2. The 
fixed cells on the slide were immersed six times for one second each 
time into solution 3 and the solution was allowed to drip off. The slide 
was rinsed with buffer solution pH 7.2 according to WEISE. The slide 
was dried in air.The morphology of the cells was examined and 
photographed. The number of differentiated and undifferentiated cells 
were counted and the %differentiation was calculated as follows: 
%differentiation = (the no. of differentiated cells / the total no. of 
cells) X 100%. 
3.2.6 Assays of the Immunorestorative Activities ofK24 CPS 
3.2.6.1 Assay of in vivo Immunorestorative Activities ofK24 
CPS in EAT-bearing Mice 
BALB/c mice were divided in groups of five and each injected i.p. with 
K24 CPS, PBS as control or none as normal according to following 
regimen. 
" P ^ K24 CPS-treated group Control group Normal group 
-1, -2，0’ 1, 2 20|ig K24 CPS/0.2mlPBS/ 0.2mlPBS/ 
mouse/day mouse/day 
~0 10^ EAT cells/ 10^ EAT cells/ 
0.2ml PBS/mouse 0.2ml PBS/mouse 
7 Mitogenic Assay of splenocytes to mitogens 
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After regimen, the BALB/c mice of each group were sacrificed and the 
spleens were removed and grinded with 4-5 ml 10 % FCS-RPMI per 
spleen. The spleen cells were centrifuged at 500 rpm for 20 s to remove 
the connective tissues. The supernatant was obtained and washed at 
2000 rpm for 5 min. The pellet was resuspended with 2 ml 10 % FCS-
RPMI and cetrifuged at 2000 rpm for 5 min. The pellet was resuspended 
with 2 ml 10 % FCS-RPMI. Cell density was determined by trypan blue 
exclusion method. The cell density of the suspension was adjusted to 5 x 
106 cells/ml. 100 |il cell suspension (5 x 10^ cells) was seeded in each 
well of flat-bottomed 96-well microplate. Serial dilutions of Con A and 
LPS were prepared. 100 i^l of Con A or LPS of different serial 
concentrations or 10 % FCS-RPMI as control were added to the 
splenocyte-containing wells to make up the well volume to 200 i^l. The 
plate was incubated at 37^0 humidified 5% CO2 for 48 h. 
Six h prior to the end of incubation, the cells were pulsed with 50 i^l 10 
^iCi/ml ^H-thymidine (0.5^iCi) per well. The plate was subjected to one 
cycle of freezing and thawing to lyse the cells. The cells were harvested 
onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of ^H-thymidine into DNA of the 
splenocytes was determined by a liquid scintillation counter. The data 
were expressed as mean counts per min.(CPM) 士 S.D. The Stimulation 
Index (S.I.) is calculated as follows: 
S.L= CPM ofthe treated group/ CPM of the control group 
The graph ofS.I. was plotted against Con A or LPS concentrations. 
3.2.6.2 Assay ofin vitro Immunorestorative Activities ofK24 
CPS in Mice bearing 10-day-old-EAT 
BALB/c mice were divided in groups of five and each injected i.p. with -
105 EAT cells in 0.2ml PBS/mouse or, PBS as control. 
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After 10 day, the BALB/c mice of each group were sacrificed and the 
spleens were removed and grinded with 4-5 ml 10 % FCS-RPMI per 
spleen. The spleen cells are centrifuged at 500 rpm for 20 s to remove 
the connective tissues. The supernatant was obtained and washed at 
2000 rpm for 5 min. The pellet was resuspended with 2 ml 10 % FCS-
RPMI and cetrifuged at 2000 rpm for 5 min. The pellet was resuspended 
with 2 ml 10 % FCS-RPMI. Cell density was determined by trypan blue 
exclusion method. The cell density of the suspension was adjusted to 5 x 
106 cells/ml. 100 i^l cell suspension (5 x 10^ cells) was seeded in each 
well of flat-bottomed 96-well microplate. Serial dilutions of K24 CPS 
were prepared. 100 i^l ofK24 CPS of different serial concentrations or 
10 % FCS-RPMI as control were added to the splenocyte-containing 
wells to make up the well volume to 200 ^1. The plate was incubated at 
370c humidified 5% CO2 for 48 h. 
6 h prior to the end of incubation, the cells were pulsed with 50 i^l 10 
^iCi/ml ^H-thymidine (0.5^Ci) per well. The plate was subjected to one 
cycle of freezing and thawing to lyse the cells. The cells were harvested 
onto a glass fibre filter with distilled water by a cell harvester. The glass 
fibre filter was dried. Incorporation of ^H-thymidine into DNA of the 
splenocytes was determined by a liquid scintillation counter. The data 
were expressed as mean counts per min.(CPM) 土 S.D. The Stimulation 
Index (S.I.) is calculated as follows: 
S.I.= CPM ofthe treated group / CPM of the control group 
The graph ofS.I. was plotted against K24 CPS concentrations. 
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4. Extraction and Characterization of Klebsiella 
pneumoniae K24 Capsular Polysaccharide (K24 CPS) 
4.1 Preparation of Klebsiella pneumoniae K24 CPS Capsular 
Polysaccharide (K24 CPS) 
After extraction, the 4.7118g crude sample was obtained. 1.7462 g crude 
sample was used in the purification using Cetavlon precipitation and 
stepwise alcohol precipitation and the remaining crude sample was kept 
as stock. 0.7473g purified sample was obtained. 
4.2 Acetic Acid Treatment ofK24 CPS 
19 mg purified K24 CPS was treated with acetic acid. After treatment, 
17 mg acetic acid-treated sample was obtained. 
4.3 Gel Filtration 
As shown in Fig.4.1, K24 CPS was eluted at 111.6 ml as a single peak 
by Sepharose CL-2B chromatography and the void volume was 
estimated as 108 ml by using dextran of average molecular weight of5-
40 million, indicating that the K24 CPS was eluted in the void volume 
and the molecular weight of K24 CPS was greater than 5 million. 
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Purification of K24 on Sepharose CL-2B 
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Figure 4.1 Gel filtration of K24 CPS. K24 CPS (6.7 mg) was 
dissolved 13.4 ml 0.9 % NaCl and 3.5 ml was applied on to a 
Sepharose CL-2B (Pharmacia) column (2.6 cm x 57 cm). 
Fractions were eluted with water. Fractions of 4.95 ml were 
obtained at flow rate of 19.8 ml/h. The relative amount of 
carbohydrate in each fraction was determined by the phenol-
sulphuric acid method (Absorbance at 485 nm). 
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4.4 Carbohydrate and Protein contents ofK24 CPS 
The carbohydrate content of K24 was determined by phenol-sulphuric 
acid method (Dubois et al, 1956) using the carbohydrate standard curve 
(Fig.4.2). It was found that K24 CPS contain 61.7932149 % (w/w). The 
protein content ofK24 was determined by using BCA Assay Kit (Pierce, 
Rockford, IL) using the protein standard curve (Fig.4.3). It was found 
that K24 CPS contain only 1.27652% 土 0.00021o/o (w/w). 
K24 CPS was found to contain mainly carbohydrate and about 1 % 
protein. From the results, the purified K24 CPS was five million when 
compared to Dextran standards profile. 
4.5 Cytotoxicity Assay using Artemia franciscana (Brine 
Shrimp) 
The toxicity ofK24 CPS had been estimated by the brine shrimp assay. 
The brine shrimp used in the assay is Artemia franciscana. 
The shrimp eggs were hatched in artificial sea water for 36-48 h at 22-
290C. Then , they were mixed with K24 CPS at different concentrations 
and hippuric acid was used as positive control. After 24-h incubation, 
the numbers of deaths and survivors were recorded and toxicity was 
expressed as LC50. LC50 is the concentration of sample which causes 
50% oftotal shrimp death and determined by Reed-Muench method (A. 
Aszalos 1981). This method assumes that shrimps that survived with a 
given concentration would also have survived at any lower • 
concentration 
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Figure 4.2 Carbohydrate standard curve for the phenol-
sulphuric acid method. The relationship between the 
absorbance at 485 nm and the concentration of glucose was 
linear. 
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Figure 4.3 Protein standard curve. The relationship between 
absorbance at 562 nm and the concentration of BSA was found 
to be linear. 
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and conversely shrimps that died with a certain concentration would 
have also died at any other higher concentration. Thus, the information 
from any one group can be added to that of the other group in the range 
of concentration tested. The accumulated number of deaths and 
survivors were plotted respectively against the log[concentration] of the 
test sample. The two curves will intercept at the concentration where the 
number of survivors is equal to the number ofdeaths. 
For hippuric acid, the two curves intercept at log concentration of 2.2 
(Fig.4.4). For K24 CPS, the two curves do not intercept in the range of 
sample concentration tested, indicating that the exact LC50 ofK24 CPS 
could not be found but it was larger than the highest concentration of 
K24 CPS used in the assay (Fig.4.5). 
By using this method, we found that the LC50 of hippuric acid is about 
158.489 \xg/m\ and that ofK24 CPS is higher than lOOO^g/ml. Thus, 
K24 CPS was found to be nontoxic in vivo (Table 4.1). 
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Estimation of LC50 of Hippuric Acid 
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Figure 4.4 Estimation of LC50 of hippuric acid by plotting the 
Reed-Muench accumulated deaths and survivors on the same 
set of axes. The two curves intersected at the 50% lethal dose 
required for the shrimp population. 
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Estimation of L C ^ of K24 Polysaccharide 
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Figure 4.5 Estimation of LC50 of K24 CPS by plotting the 
Reed-Muench accumulated deaths and survivors on the same 
set of axes. The two curves did not intersect so that the 50% 
lethal dose required for the shrimp population could not be 
estimated. 
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Table 4.2 The lethal concentration (LC50) of hippuric acid and 
K24 CPS. 
l r ^ ^ F s ^ ^ ^ ( ^ ^ s / m i ) 
^ i r i ^ fo^^^"^^ 
K24 CPS > 1 _ 
LC50 of hippuric acid was found to be 158.489 jig/ml while K24 
CPS was greater than 1000 jig/ml. 
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5. Immunomodulatory Effects of K24 CPS 
5 1 The Effect of K24 CPS in vitro Mitogenic Assay of K24 
CPS using Murine Splenocytes 
In the in vitro mitogenic assay ofK24 CPS, splenocytes were obtained 
from spleens ofBALB/c mice and cultured with K24 CPS at different 
concentration or cuture medium alone as control. 
The result showed that K24 CPS stimulated the proliferation of 
splenocytes in a dose-dependent manner. For the cells cultured with K24 
CPS in the presence ofPolymyxin B, the mitogenic effect ofK24 CPS 
'was much reduced because Polymyxin B is a polycationic antibiotic 
which binds directly and non-specifically to anionic and acidic K24 CPS 
and neutralize its mitogenic activity (Fig.5.1). Similar result was 
observedforLPS(Fig.5.2) 
In order to illustrate the mitogenic effect of K24 CPS was not due to 
LPS contamination, K24 CPS was treated with acetic acid before 
mitogenic assay. In the treatment, the sample was boiled in 2 % acetic 
acid for 90 min so that toxic and immunostimulating lipid A would be 
depleted from LPS and removed by centrifugation and dialysis, thus, the 
effect of LPS was eliminated. And the acetic acid-treated sample was 
obtained. It was shown that acetic acid treatment could not affect 
significantly the mitogenic effect ofK24 CPS (Fig.5.3) while that of 
LPS could be completely abolished (Fig.5.4). 
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Figure 5.1 The effect of polymyxin B on the mitogenic effect of 
K?4 CPS on murine splenocytes. 5 x 105 murine splenocytes 
were co-cultured with K24 CPS in different concentrations m 
the presence or absence of polymyxin B. After t h m ^ u b a t i : 
he L t u r e d cells were pulsed with 0.5^Ci/well ^H^Td^ and the 
radioactivity incorporation was determined. Results were 
expressed as mean S.I. 土 S.D. 
69 -
Mifnq6nic Eff^r.t of LipoDolvsaccharide 
on M',"n^ Splenocvtes 
6干 ^ ^ ^ ^ \ ^ ^ _ ^ ^ " " " ^ " ^ ^ ^ " " ^ "“ ^ ^ 
5 � / 
40 - [ 








10 - y Z ^ 
^ 
m-w^ 
0 K- 1 1 ~T" ‘ ‘ 
0 20 40 60 80 100 120 
Concentration of LPS (MQ/ml) 
- ^ LPS 
m LPS in the presence of 5^jg/ml PMB 
Figure 5.2 The effect of polymyxin B on the mitogenic effect of 
LPS on murine splenocytes. 5 x 105 murine splenocytes were 
co-cultured with LPS in different c o n = t r a t H > : u i he 
presence or absence ofpolymyxin B. After 4?-^^«^；；，? '^' 
L t u r e d cells were pulsed with 0.5^Ci/well 3H-^dR and the 
radioactivity incorporation was determined. Results were 
expressed as mean S.I. 土 S.D. 
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Figure 5.3 The mitogenic effect of K24 CPS after acetic acid 
treatment on murine splenocytes. 5 x 10^ murine splenocytes 
were co-cultured with K24 CPS in different 了 二 = 
with or without the treatment of 2% acetic acid for 90 mm. 
After 42-h incubation, the cultured cells were pulsed with 
0.5^Ci/well 3H-TdR and the radioactivity incorporation was 
determined. Results were expressed as mean S.I. 土 ^ ^.^ 
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Figure 5.4 The mitogenic effect of LPS after acetic acid 
treatment on murine splenocytes. 5 x 10^ m u r i n e splenocytes 
were co-cultured w i t h L P S i n different c o n c e n t r a t i o n s m t = o r 
without the treatment of 2�/<> acetic acid for 90 ^ ^ - ' f ^ ^ l ' ^ ^ 
incubation, the cultured cells were pulsed with 0.5^Ci/well H-
TdR and the radioactivity incorporation was determined. 
Results were expressed as mean S.I. 士 S.D. 
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5.2 The in vivo Mitogenic Effect of K24 CPS on Murine 
Splenic Lymphocytes 
Table 5.1 showed that the ratio of spleen-to-body weight ratio was 
significantly increased after i.p. injection ofK24 CPS. The enlargement 
of spleen could be due to the induction of splenic lymphocytes 
proliferation by K24 CPS, as shown by the increased 3H-TdR 
incorporation of splenic lymphocytes from K24 CPS-treated mice. 
These results indicated that K24 CPS is mitogenic to mouse splenic 
lymphocytes in vivo. 
5.3 The Effect ofK24 CPS on the Production ofInterleukin-2 
(IL-2)-like substance by Murine Splenocytes 
The IL-2 standard curve was constructed using murine IL-2 as standard 
(Fig.5.5). The relationship between CPM and IL-2 concentration was 
linear. K24 CPS could augment the IL-2 production of splenocytes in a 
dose-dependent manner (Fig.5.6) and show maximum augmentation of 
IL-2 ofabout 0.15U/ml at K24 CPS of 50 i^g/mL 
« 
5 4 The effect ofK24 CPS on the in vitro Stimulation of 
Murine Macrophage Nitric Oxide (NO) Production 
Thioglycollate-elicited peritoneal macrophages were cultured with K24 
CPS or LPS as positive control at different concentrations for 24 h. NO 
is highly unstable and cannot be readily assayed. Since NO is converted 
to stable nitrite in aqueous solution, NO product is monitored by 
measuring 
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Table 5.1 The Mitogenic Effect of K24 CPS in vivo 
Mice iniected with Spleen-to-body weight 'H-TdR incorporation~" 
ratio (CPM) 
- ^ 0.003979i7.81 xlO^ 4128.158±39.860 
K24 CPS 0.005537i9.08 xlO_4 * 8154.408±96.325 ** 
(50 fig/mouse) 
On day 0，50 jig K24 CPS or PBS was injected i.p. into each 
BALB/c mice. On day 3，the spleen-to-body weight ratio and 
the 3H-TdR incorporation into the splenic lymphocytes were 
determined.The spleen and the body of each mice of the two 
groups was weighed. After the ratio was determined, the 
splenic lymphocytes were isolated and seeded into a 96-well 
plate at 5 x 10^ cells/well and were pulsed with 0.5jiCi/weIl H-
XdR for 6hand the radioactivity incorporation was 
determined. The difference between the PBS-treated and K24 
CPS-treated groups was determined by the Student's t-test.* ： 
P<0.005 and ** : P<0.001 
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Figure 5.5 The interleukin-2 (IL-2) standard curve. Day 0，Con 
A Blast Cells was prepared from BALB/c splenocytes at 2 x 10 
cells/ml in RPMMO% FCS containing 2.5jig/ml Con A in the 
wells of flat-bottomed 6-well culture plate for 72 h at 37 C^ in 
humidified 5% C02. On day 3，5 x 10^ (lOO i^l) Con A blast cells 
were ultured with 100^1 IL-2 standards for 18 h at 3 7 � C m 
humidified 5% CO2. The cells were pulsed with 50 i^l 
(lO^Ci/ml) 3H-TdR (0.5^iCi) for 6 h at 3 7 � C in humidified 5% 
CO2 and the radioactivity incorporation was determined by 
liquid scintillation counting. The relationship between CPM 
and IL-2 concentration was found to be linear. 
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The Effect of K24 CPS on the IL-2 Production of Murine 
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Figure 5.6 The effect of K24 CPS on the interleukin-2 (IL-2)-
like substances production of murine splenocytes. Day 0，Con 
A Blast Cells was prepared from BALB/c splenocytes at 2 x 10 
cells/ml in RPMI-10% FCS containing 2.5^g/ml Con A in the 
wells of flat-bottomed 6-well culture plate for 72 h at 37 "C in 
humidified 5% CO2. On day 1，5 x 10^ BALB/c splenocytes 
were co-cultured with 1000 K24 CPS of different serial 
dilutions in the wells of flat-bottomed 96-well culture plate for 
48 h at 3 7 � C in humidified 5% CO .^ On day 3，5 x 10^ (lOOjd) 
Con A blast cells was co-cultured with lOO i^l splenocyte 
conditioned medium for 18 h at 3 7 � C in humidified 5% CO .^ 
The cells were pulsed with 50 i^l (lO^iCi/ml) ^H-TdR (0.5^iCi) 
for 6 h at 3 7 � C in humidified 5% CO2 and the radioactivity 
incorporation was determined by liquid scintillation counting. 
The CPM was measured and interleukin-2 (IL-2) 
concentration was found from interleukin-2 (IL-2) standard 
curve. 
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supernatant nitrite concentration. 50^d of culture supernatant were 
mixed with an equal volume of Griess reagent. The absorbance at 
550nm was measured and nitrite concentration was found from nitrite 
standard curve. The standard curve showed a linear relationship between 
the absorbance at 550nm and the nitrite concentration (Fig.5.7). 
K24 CPS stimulated NO production by macrophages in a dose-
dependent manner (Fig.5.8). The optimal stimulation was observed at 
concentration of 50^lg/ml and the NO production was increased by 
about six-fold when compared to the unstimulated macrophages. 
LPS acted as a positive control in the assay since it is a potent 
macrophage activator, showing that the macrophages used in the assay 
was highly responsive to activators (Fig.5.9). 
5.5 The effect ofK24 CPS on the in vitro Stimulation of 
Macrophage Interleukin-1-like Production 
IL-1 plays a very important role in regulating the transcription of genes 
for IL-2 receptor (IL-2R) (Hagiwara, et al. 1987), therefore, the 
presence ofIL-1 can induce the expression of more IL-2R. In the assay, 
IL-2 was employed to saturate the IL-2R on the surfaces of the 
thymocytes. In the presence ofIL-1, more IL-2R was expressed on the 
surfaces ofthe thymocytes and could be available for binding with IL-2, 
giving rise to proliferation of thymocytes. Therefore, proliferation of 
thymocytes can act as a mean of the quantity of IL_ 1. 
The standard curve of IL-1 was constructed using murine IL-1. The 
relationship between CPM and IL-1 concentration was found to be 
linear(Fig.5.10). 
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Figure 5.7 The Standard Curve ofsodium nitrite (NaNO2). The 
linear relationship between the absorbance at 550 nm and the 
sodium nitrite concentration. 
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Figure 5.8 The stimulatory effect of K24 CPS on the nitric 
oxide (NO) production of macrophage. Three BALB/c mice 
was injected i.p. with 3% thioglycollate. After 3 days, 
peritoneal macrophages were harvested and 5 x lU 
Lcrophages were cultured with K24 CPS at different 
concentrations for 24 h. NO is converted to stable n i tntem 
aqueous solution and NO product is monitored by measuring 
supernatant nitrite concentration. 50 i^l of culture supernatant 
were mixed with an equal volume of Griess reagent. The 
absorbance at 550nm was measured and nitrite concentration 
was found from nitrite standard curve. 
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Figure 5.9 The stimulatory effect of LPS on the nitric oxide 
(NO) production of macrophage. Three BALB/c mice was 
injected i.p. with 3% thioglycollate. After 3 days, peritoneal 
macrophages were harvested and cultured with LPS at 
different concentrations for 24 h. NO is converted to stable 
nitrite in aqueous solution and NO product is monitored by 
measuring supernatant nitrite concentration. 50^il of culture 
supernatant were mixed with an equal volume of Gness 
reagent. The absorbance at 550nm was measured and mtrite 
concentration was found from nitrite standard curve. 
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Figure 5.10 The standard curve of interleukin-1 (IL-1). 1 x 10^ 
BALB/c thymocytes were cultured with interleukin-1 (IL-1) of 
different concentrations in the presence of IL-2 (lOU/ml). 
After 66h incubation at 37«C, the cultured cells were pulsed 
with 0.5^iCi/well 'H-TdR and the radioactivity incorporation 
was determined. The relationship between the CPM and the 
interleukin-1 (IL-1). concentration was linear. 
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As shown in Fig.5.11, K24 CPS could induce IL-l-like production of 
macrophage ofgreaterthan 1.5U/ml at concentration of6.25^ig/ml. 
5.6 The effect ofK24 CPS on invivo Migration ofMacrophage 
On day 0, BALB/c mice in group of four were either injected i.p. with 
50 i^g K24 CPS in 0.2 ml PBS or 0.2 ml PBS. On day 3, peritoneal 
exudate cells of individual mouse was harvested and counted. The 
results showed that i.p. injection of K24 CPS could significantly 
enhanced the migration ofmacrophages into the peritoneal cavity ofthe 
BALB/c mice (P<0.05) (Fig.5.12). 
5 7 The effect ofK24 CPS in vitro Stimulation ofMacrophage 
Tumour Necrosis Factor- a (TNF-a) Production 
The standard curve of TNF-a was constructed using murine TNF-a 
(Fig.5.13a). The relationship between the % cytotoxicity and log (TNF_ 
a concentration) was linear. Fig.5.13b showed K24 CPS exhbit in vitro 
stimulation TNF-a production of murine thioglycollate-elicited 
peritoneal macrophage in dose-dependent fashion (Fig.5.14a). The 
amount of TNF-a was forther determined by TNF-a ELISA test kit 
(Fig.5.14b). 
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Figure 5.11 On day 1，3 BALB/c mice was each injected i.p 
with 1ml 3% Brewer thioglycollate. On day 4，peritoneal 
macrophages were harvested and 5 x 105 macrophages per 
well were cultured in the 96-well plate with K24 CPS at 
different concentrations for 24 h. On day 5，1 x 10 BALB/c 
thymocytes per well were co-cultured with 50 i^l macrophage-
conditioned medium in the presence of IL-2 (10 U/ml) m 
another 96-well plate at 37�C humidified 5% CO^ for 66h. 
After incubation, the cultured cells were pulsed with 
0.5^iCi/well 3H-TdR and the radioactivity incorporation was 
determined. 
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Figure 5.12 The effect of K24 CPS on the in vivo migration of 
peritoneal macrophages. The method described by Gervais et 
al (1984) was followed with minor modification. On day U, 
BALB/c mice in group of four were either injected i.p. with 50 
„g K24 CPS in 0.2 ml PBS or 0.2 ml PBS. On day 3，peritoneal 
exudate cells of individual mouse was harvested and allowed to 
adhere to the petri dish for 2-4 h. The adhered cell was 
trypsinised and counted. The difference between the PBS-
treated and K24 CPS-treated groups was determined by the 
Student's t-test. * : P<0. 05. 
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Figure 5.13a The standard curve of tumour necrosis factor- a 
(XNF- a) L929 cells which have been seeded for 24h were 
cultured with tumour necrosis factor- a (TNF- a) of different 
concentrations. After 24h incubation at 37«C, the cells were 
washed and stained with neutral red. The dye uptake by L929 
cells was determined by measuring the absorbance at 540nm 
after lysing the cells in 1% SDS solution. The % cytotoxicity 
was calculated as follows: 
o/o cytotoxicity = (C - T)/C 
where C = Absorbance at 540nm of control group 
T = Absorbance at 540nm of TNF- a-treated group 
The relationship between the % Cytotoxicity and the log TNF_ 
a concentration was linear. 
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Figure 5.13b The standard curve oftumour necrosis factor- a 
(TNF- a) by TNF- a ELISA test kit. 
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Figure 5.14a The stimulatory effect ofK24 CPS on the tumour 
necrosis factor- a (TNF- a) production of macrophage. Three 
BALB/c mice was injected i.p. with 3% thioglycollate. After 3 
days, peritoneal macrophages were harvested and cultured 
with K24 CPS at different concentrations for 24 h. 50 i^I of 
culture supernatant were transferred to L929 cells which have 
been seeded for 24h. After 24h incubation at 37«C, the cells 
were washed and stained with neutral red. The dye uptake by 
L929 cells was determined by measuring the absorbance at 
540nm after lysing the cells in 1% SDS solution. The % 
cytotoxicity was calculated and tumour necrosis factor- a {TNF-
a) concentration was found from tumour necrosis factor- a 
(TNF- a) standard curve. 
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Figure 5.14b The stimulatory effect ofK24 CPS on the tumour 
necrosis factor- a (TNF- a) production of macrophage. Three 
BALB/c mice was injected i.p. with 3% thioglycollate. After 3 
days, peritoneal macrophages were harvested and cultured 
with K24 CPS at different concentrations for 24 h. The 
concentration of TNF- a in 50 i^l of culture supernatant were 
determined by TNF- a ELISA test kit. Tumour necrosis factor-
a (TNF- a) concentration was found from tumour necrosis 
factor- a (TNF- a) standard curve. 
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6. In vitro anti-tumour effect of K24 CPS 
6.1 The in vitro Cytostatic effect of K24 CPS on the 
Suppression ofEAT growth 
K24 CPS was found to be non-toxic to normal organisms in vivo as 
determined by the cytotoxiciy assay using brine shrimp in the 
Extraction and Characterisation of K24 CPS. The in vitro anti-
tumour activity of K24 CPS was studied. It was found that K24 CPS 
could suppress the proliferation of EAT cells in vitro in a dose-
dependent fashion (Fig.6.1). The % Suppression of EAT cell 
proliferation was found to be about 80% at K24 CPS of concentration of 
200^igAnl but the % Suppression was below 20% at K24 CPS of 
concentration ofbelow 50^ig/ml. 
The in vitro anti-tumour activity of other high molecular weight 
polysaccharides such as dextran and LPS were also studied. The results 
showed that dextran and LPS could not affect the proliferation ofEAT 
cells (Fig.6.2 and 6.3) and thus have no cytostatic effect on the 
proliferation ofEAT cell. Therefore, the cytostatic effect ofK24 CPS on 
the proliferation of EAT cells may be quite unique to the structure of 
K24 CPS since some other polysaccharide showed no cytostatic effect. 
6.2 The effect ofK24 CPS on cell cycle ofEAT cells 
1 X 105 EAT were co-cultured 200 ^ig/ml K24 CPS or 10 %-FCS RPMI 
medium as control in the wells of24-well plate. After 48-h incubation, 
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Figure 6.1 The in vitro cytostatic effect of K24 CPS on EAT 
growth. 1 X 104 EAT were co-cultured with K24 CPS in 
different concentrations in the wells of 96-well plate. After 42-
h incubation, the cultured cells were pulsed with 0.5^iCiMell 
3jj_TdR and the radioactivity incorporation was determined. 
Results were expressed as % Suppression. 
% Suppression = [(CPMc�„tr�rCPMK24CPs)/CPMc�„J x 100% 
where CPM,,„troi is the mean count per minute of the 
control group and CPMK24 cps is the mean count per minute of 
the K24 CPS-treated group. 
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Figure 6.2 The in vitro cytostatic effect of dextran on EAT 
growth. 1 X 10^ EAT were co-cultured with dextran in different 
concentrations in the wells of 96-well plate. After 42-h 
incubation, the cultured cells were pulsed with 0.5^Ci/weIl H-
TdR and the radioactivity incorporation was determined. 
Results were expressed as % Suppression. 
% Suppression = [(CPMc�„tr��CPMdextrJ/CPMc�„tr�l�X 100% 
where CPM^troi is the mean count per minute of the 
control group and CPM e^xtran is the mean count per minute of 
the dextran-treated group. 
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Mean CPM ofthe control group = 168264.7333 ± 621.1546 
Figure 6.3 The in vitro cytostatic effect ofLPS on EAT growth. 
1 X 104 EAT were co-cultured with LPS in different 
concentrations in the wells of 96-well plate. After 42-h 
incubation, the cultured cells were pulsed with 0.5jiCi/well H_ 
TdR and the radioactivity incorporation was determined. 
Results were expressed as % Suppression • 
% Suppression = [(CPMe�„tr�rCPMLPs)/CPMe�„trJ ^ 100% 
where CPMeo„troi is the mean count per minute of the 
control group and CPMiPs is the mean count per minute of 
the LPS-treated group. 
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the cultured cells were fixed with 70% ethanol at 4^C for 24 h. The cells 
were then stained with propidium iodide at room temperature for 30min. 
The cell cycle pattem of the cells was determined by FACSORT flow 
cytommeter. 
The cell cycle patterns of EAT cell populations in the presence and 
absence of200 i^g/ml K24 CPS were compared in Fig.6.4. The two cell 
populations showed similar typical cell cycle patterns. By the Cell Fit 
program, for the control, the % Go/Gi phase, % S phase and % G2 + M 
phase are 45, 35.5, and 19.5 respectively. For the cells with K24 CPS 
(200 ^ig/ml), the % Go,Gi phase, % S phase and % G2 + M phase are 
49.7, 30.9, and 19.4 respectively. The results showed that K24 CPS 
could not suppress the proliferation of EAT cells by exerting blocks in 
the phases ofthe cell cycle ofEAT cells. 
6.3 Study of the cytostatic effect of K24 CPS on EAT cells 
using Western Analysis 
6.3.1 Pattern ofPhosphotyrosine Proteins 
EAT cells were co-cultured with 200 i^gAnl K24 CPS in the cell density 
of 1 X 104 in 100 i^l complete RPMI medium in the 60 mm petri dish. 
After 24-h incubation, the phosphotyrosine proteins were detected by 
anti-phosphotyrosine antibody (mouse, clone PY20; Santa Cruz, South 
San Francisco, CA). It was shown that the tyrosine phosphorylation of 
some proteins of EAT cells reduced after 24-h incubation with 200 
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Figure 6.4 The effect of K24 CPS on cell cycle of EAT cells. 1 x 
10^ EAT were co-cultured 200 ^g/ml K24 CPS (a) or 10 %-
FCS RPMI medium (b) in the wells of24-well plate. After 48-h 
incubation, the cultured cells were fixed with 70% ethanol at 
40c for 24 h. The cells were then stained with propidium 
iodide at room temperature for 30min. The cell cycle pattern 
of the cells was determined by FACSORT flow cytommeter. 
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Figure 6.5 Pattern of phosphotyrosine proteins in EAT cells 
after 24-h incubation with various concetrations of K24 CPS. 
The proteins were detected by anti-phosphotyrosine antibody 
(mouse, clone PY20; Santa Cruz, South San Francisco, CA). 
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6.3.2 Pattern ofPhosphoserine Proteins 
EAT cells were co-cultured with varous concentartions of K24 CPS in 
the cell density of 1 x 10^ in 100 |il complete RPMI medium in the 60 
mm petri dish. After 24 or 48-h incubation, the phosphoserine proteins 
were detected by anti-phosphoserine antibody (rabbit, Zymed, South 
San Francisco, CA). There was no obvious trend of alteration of the 
phosphoserine protein level with respect to the concentration of or the 
incubation time with K24 CPS (Fig.6.6). 
6.3.3 Pattern ofPhosphothreonine Proteins 
EAT cells were co-cultured with varous concentartions of K24 CPS in 
the cell density of 1 x 10^ in 100 i^l complete RPMI medium in the 60 
mm petri dish. After 24 or 48-h incubation, the proteins were detected 
by (Fig.6.7a) anti-phosphothreonine antibody (mouse, clone PT-5H5, 
Zymed, South San Francisco, CA) and (Fig.6.7b) anti-phosphothreonine 
antibody (mouse, clone PT-5H5, Zymed, South San Francisco, CA) with 
20 mM anti-phosphothreonine inhibitor (0-phospho-L-threonine, 
Zymed, South San Francisco, CA). The anti-phosphothreonine inhibitor 
was used with anti-phosphothreonine primary antibody to distinguish 
between specific versus non-specfic binding of the primary antibody in 
Westem blotting by blocking the specific binding of anti-
phosphothreonine primary antibody. From Fig.6.7a and b，after 
detection by using anti-phosphothreonine primary antibody with anti-
phosphothreonine inhibitor, most ofthe bands observed in Fig.6.7a were 
disappeared in Fig.6.7b, indicating that most of the bands observed in 
Fig.6.7a was due to the specific binding of anti-phosphothreonine 
primary antibody. 
96 -
Concentration ofK24 CPS (^ig/ml) 
kD 0 200 0 50 100 200 
1 0 6 " ^ “ iMpw «..-• «wM» mmm.…崎.*** 
SOmm^ 
.^ ^^ t^fte 'WiitutKt^' _ ^ m^^i^^ j^ ^^ |^k :"iiMili^ iMfit^ . 
49 5 ^^^ *iir^*^ mm wm 導嶋"舉 
32.5-i^ 
mmm *•'_, •'‘• mmm- •• ..'. •:—•«> 
27.5 • ! • 
18.5 “ ^ 
24 h 48h 
Figure 6.6 Pattern of phosphoserine proteins in EAT cells after 
24 or 48-h incubation with various concetrations of K24 CPS. 
The proteins were detected by anti-phosphoserine antibody 
(rabbit, Zymed, South San Francisco, CA). 
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Figure 6.7 Pattern of phosphothreonine proteins in EAT ceils 
after 24 or 48-h incubation with various concetrations of K24 
CPS. The proteins were detected by (a) anti-phosphothreonine 
antibody (mouse, clone PT-5H5, Zymed, South San Francisco, 
CA) and (b) anti-phosphothreonine antibody (mouse, clone 
PT-5H5, Zymed, South San Francisco, CA) with 20 mM anti-
phosphothreonine inhibitor (0-phospho-L-threonine, Zymed, 
South San Francisco, CA). 
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It was shown that the level of threonine phosphorylation of some 
proteins ofEAT cells reduced after 24-h incubation with 200 i^g/ml K24 
CPS (Fig.6.7a). After 48-h incubation, the level of threonine 
phosphorylation of some proteins of EAT cells decreased with 
increasing concentration ofK24 CPS and reached minimum at K24 CPS 
concentration of200 p,g/ml. 
6.3.4 Level of c-fos 
EAT cells were co-cultured with varous concentartions of K24 CPS in 
the cell density of 1 x 10^ in 100 i^l complete RPMI medium in the 60 
mm petri dish. After 24 or 48-h incubation, c-fos was detected by anti-c-
fos antibody (Ab-3, mouse, clone CS93.1.18; Calbiochem, Oncogene 
Research Products, Cambridge, MA). There was no obvious trend of 
alteration of the c-fos level with respect to the concentration of or the 
incubation time with K24 CPS (Fig.6.8). 
6.3.5 Level of c-jun 
EAT cells were co-cultured with varous concentartions of K24 CPS in 
the cell density of 1 x 10^ in 100 i^l complete RPMI medium in the 60 
mm petri dish. After 24 or 48-h incubation, c-jun was detected by anti-c-
jun antibody (Ab-3, mouse, clone 76; Calbiochem, Oncogene Research 
Products, Cambridge, MA). It was shown that the level of c-jun ofEAT 
cells reduced after 24-h incubation with 200 i^g/ml K24 CPS (Fig.6.9). 
After 48-h incubation, the level of c-jun of EAT cells decreased with 
increasing concentration ofK24 CPS and reached minimum at K24 CPS 
concentration of200 ^g/ml (Fig.6.9). 
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Figure 6.8 Levels of c-fos in EAT cells after 24 or 48-h 
incubation with various concetrations of K24 CPS. c-fos was 
detected by anti-c-fos antibody (Ab-3, mouse, clone CS93.1.18; 
Calbiochem, Oncogene Research Products, Cambridge, MA). 
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Figure 6.9 Levels of c-jun in EAT cells after 24 or 48-h 
inLbation with various concetrations of K24 CPS. c fos was 
detected by anti-cjun antibody (Ab-3，mouse clone 76; 
Calbiochem，Oncogene Research Products, Cambridge, MA). 
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6.3.6 Level ofc-myc 
EAT cells were co-cultured with varous concentartions of K24 CPS in 
the cell density of 1 x 104 in 100 i^l complete RPMI medium in the 60 
mm petri dish. After 24 or 48-h incubation, c-myc was detected by anti_ 
c-myc antibody (mouse, Oncogene Science). It was shown that the level 
ofc-myc ofEAT cells remained unchanged and was low after 24 or 48-
h incubation with or without K24 CPS (data not shown). 
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7 � T h e in vivo Anti-Tumour Activities of K24 CPS 
7.1 The effect ofK24 CPS on the In vivo Suppression ofEAT 
growth 
I.p. injection of K24 CPS or LPS into BALB/c mice according to 
regimens A, B，and C as stated in the Method. K24 CPS could suppress 
the EAT growth by about 80% for regimens A and B (Fig.7.1 and 7.2)， 
and about 60% for regimen C (Fig.7.3). The differences between the 
result ofregimen A and B，and regimen C may be due to the proposal 
that the suppression of EAT growth may be mediated by the host 
immune system ofthe mice. Since K24 CPS may potentiate the immune 
components such as enchanced NK cytotoxicity in vivo (as shown in the 
following section) and increased TNF-a and NO production by 
macrophages before inoculation ofEAT cell for regimens A and B, but 
not for regimen C in which i.p. injection ofK24 CPS were given after 
the inoculation ofEAT cells. 
LPS acted as a positive control. Similar results were observed for the 
three regimens in the % Suppression of EAT growth in vivo, showing 
that the immune components were responsive to stimulants (Fig.7.4-
7.6). 
7.2 The effect ofK24 CPS on the survival ofEAT-bearing 
mice 
The results showed that the % survival of untreated BALB/c EAT_ 
bearing mice decreased to 0% after day 21, while the K24 CPS-treated 
group of mice remain 90% (Fig.7.7). K24 CPS could increase the % 
survival of EAT-bearing mice because K24 CPS may activate the 
immune components as stated above of the mice so as to suppress the 
EAT growth and increase the survival of the tumour-bearing mice. 
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Figure 7.1 The effect of K24 CPS on in vivo suppression of 
EAT growth. BALB/c mice in groups of five were injected i.p. 
with K24 CPS (20^ig K24 CPS/0.2ml PBS/mouse/day) for 5 
consecutive days (day -2 to 2). Control mice were injected with 
an equal volume ofPBS. On day 0,all mice were injected with 
EAT cells (105 EAT cells/0.2ml PBS/mouse). The number of 
EAT cells recoverable from the peritoneal cavity of each 
mouse was determined on day 7. The difference between 
groups of control and treatment was determined by Student's 
t-test. 
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Figure 7.2 The effect of K24 CPS on in vivo suppression of 
EAT growth. BALB/c mice in groups of five were injected i.p. 
with K24 CPS (20^ig K24 CPS/0.2mlPBS/mouse/day) for 5 
consecutive days (day -2 to 2). Control mice were injected with 
an equal volume of PBS. On day 0,all mice were injected with 
EAT cells (105 EAT cells/0.2ml PBS/mouse). The number of 
EAT cells recoverable from the peritoneal cavity of each 
mouse was determined on day 9. The difference between 
groups of control and treatment was determined by Student s 
t-test. 
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Figure 7.3 The effect of K24 CPS on in vivo suppression of 
EAT growth. On day 0，BALB/c mice in two groups (control 
and treatment) of five were injected i.p. with EAT cells (10 
EAT cells/0.2ml PBS/mouse). On day 5 to 8，K24 CPS (25照 
K24 CPS/0.2mlPBS/mouse/day) for 4 consecutive days. 
Control mice were injected with an equal volume of PBS: The 
number ofEAT cells recoverable from the peritoneal cavity of 
each mouse was determined on day 9. The difference between 
groups of control and treatment was determined by Student s 
t-test. 
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Figure 7.4 The effect of LPS on in vivo suppression of EAT 
growth (Regimen A). BALB/c mice in groups of five were 
injected i.p. with LPS (20^ig LPS/0.2mlPBS/mouse/day) for 5 
consecutive days (day -2 to 2). Control mice were injected with 
an equal volume of PBS. On day 0,all mice were injected with 
EAT cells (105 EAT cells/0.2ml PBS/mouse). The number of 
EAT cells recoverable from the peritoneal cavity of each 
mouse was determined on day 7. The difference between 
groups of control and treatment was determined by Student's 
t-test. ***:P<0.0005 
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Figure 7.5 The effect of LPS on in vivo suppression of EAT 
growth (Regimen B). BALB/c mice in groups of five were 
injected i.p. with LPS (20^ig LPS/0.2mlPBS/mouse/day) for 5 
consecutive days (day -2 to 2). Control mice were injected with 
an equal volume of PBS. On day 0,all mice were injected with 
EAT cells (105 EAT cells/0.2ml PBS/mouse). The number of 
EAT cells recoverable from the peritoneal cavity of each 
mouse was determined on day 9. The difference between 
groups of control and treatment was determined by Student's 
t-test. ***:P<0.0005 
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Figure 7.6 The effect of LPS on in vivo suppression of EAT 
growth (Regimen C). On day 0，BALB/c mice in two groups 
(control and treatment) of five were injected i.p. with EAT 
cells (105 EAT cells/0.2ml PBS/mouse). On day 5 to 8，LPS 
(25^ig LPS/0.2mlPBS/mouse/day) for 4 consecutive days. 
Control mice were injected with an equal volume of PBS. The 
number of EAT cells recoverable from the peritoneal cravity 
of each mouse was determined on day 9. The difference 
between groups of control and treatment was determined by 
Student's t-test. **:P<0.005 
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Figure 7.7 The effect of K24 CPS on the survival of EAT-
bearing mice. BALB/c mice in groups of twenty were mjected 
i.p. with K24 CPS (20^ig in 0.2ml PBS/mouse) or an equal 
volume of PBS for control for five consecutive days (day -2 to 
2). On day 0，1 x 10^ EAT cells were injected i.p. into each 
mouse. The % survival of the two groups were determined on 
each day after EAT inoculation. 
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7 3 The effect of K24 CPS on the in vivo induction of Natural 
Killer (NK) Cell Cytotoxicity 
In the study of in vivo induction ofNatural Killer Cytotoxicity by K24 
CPS, the cytotoxicity of NK cells was determined by 4-h CytoTox 96 
Assay Kit. 
BALB/c mice in groups of3 were injected i.v. with a single dose of 10 
^g K24 CPS or i.p. with 50 i^g K24 CPS/mouse/day for 3 consecutive 
days. The NK cytotoxicity of the two groups and normal mice were 
assayed at effector to target ratio of25 one day after the treatment. I.v. 
injection could induce a higher NK cytotoxicity on YAC-1 cells than i.p. 
injection (Fig.7.8), suggesting that i.v. injection ofK24 CPS was a more 
effective way in the in vivo induction of NK cytotoxicity than i.p. 
injection. 
Besides, the kinetics ofthe induction ofNK cytotoxicity by K24 CPS 
was also studied.Different groups ofBALB/c mice were injected iv with 
a single dose of lO i^g K24 CPS on days 1, 2 and 3 respectively and NK 
cytotoxicities ofdifferent groups were determined on day 4 at effector to 
target ratio of 50. It was shown that the NK cytotoxicity was the highest, 
about 45%, two days after i.v. injection and decreased drastically 3 days 
after the injection and NK cell cytotoxicities of normal and PBS-injected 
mice were relatively low (Fig.7.9). 
7.4 The effect of K24 CPS in vitro induction of Lymphokine-
activated Killer (LAK) Cell Cytotoxicity 
Normal and cultured splenocytes showed relatively low LAK cell 
cytotoxicities. K24 CPS could induce significant LAK cytotoxicity on " 
WEHI-164 target cells. 
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Figure 7.8 The effect of K24 CPS on in vivo induction of 
murine natural killer (NK) cell cytotoxicty. K24 CPS 
(lO^ig/mouse) in 0.2ml PBS were injected i.v. on day 0 or 
(50^g/mouse/day) in 0.2ml PBS were injected i.v. on day -2 to 0 
into BALB/c mice in groups of three respectively. On day 1， 
NK cell cytotoxicity was assayed by a 4-h Promega CytoTox-
96 Assay Kit using YAC-1 cells as target at effector-to-target 
of 25:1. Normal mice showed no significant induction of NK 
cell cytotoxicity. **•• P<0.005 
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Figure 7.9 The kinetics of the effect of K24 CPS on in vivo 
induction of murine natural killer (NK) cell cytotoxicty. On 
day 1，2，and 3，K24 CPS (lOfig/mouse) in 0.2ml PBS were 
injected i.v. into BALB/c mice in groups of three. On day 4， 
NK cell cytotoxicity was assayed by a 4-h Promega CytoTox-
96 Assay Kit using YAC-1 cells as target at effector-to-target 
of25: l . Normal and PBS-treated mice showed no significant in 
vivo induction ofNK cell cytotoxicity. ***: P<0.0005 
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Furthermore, combination of IL-2 and K24 CPS (%cytotoxicity of 
above 60%) was more effective in the in vitro induction of LAK cell 
cytotoxicity than treatment with IL-2 or K24 CPS alone (%cytotoixicitiy 
ofabout 40%) (Fig.7.10). Therefore, K24 CPS have enhancement effect 
with IL-2 in the in vitro induction ofLAK cell cytotoxicity. 
7.5 The effect ofK24 CPS on the in vivo Induction of 
Lymphokine-activated Killer (LAK) Cell Cytotoxicity 
As shown in Fig. 7.11, normal splenocytes showed relatively low LAK 
cell cytotoxicities when compared to that of cultured splenocytes from 
K24 CPS-injected mice, showing that i.p. injection of K24 CPS could 
induce LAK cell cytotoxicity in vivo. Further culture of splenocytes 
isolated from K24 CPS-injected mice with K24 CPS and/or IL-2 could 
in vitro further induce significant LAK cell cytotoxicity. Furthermore, 
combination ofIL-2 and K24 CPS was more effective in the induction 
ofLAK cytotoxicity than treatment with IL-2 or K24 CPS alone. 
When comparing results of the treatments in the in vivo induction of 
LAK cell cytotoxicity with that in the in vitro induction of LAK cell 
cytotoxicity, the % cytotoxicities of the treatments in the in vivo 
induction were higher than that ofthe corresponding treatments in the in 
vitro induction, suggesting that in vivo induction could have synergistic 
effect with the in vitro induction. 
7.6 The effect ofK24 CPS on the endogenous production of 
TNF-a 
BALB/c mice in groups of five were injected i.v. with K24 CPS in 
different dose in 0.2ml PBS or an equal volume ofPBS as control. After 
1.5 h, serum was collected from each mouse of each group. The serum 
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Figure 7.10 The effect ofK24 CPS on the in vitro induction of 
lymphokine-activated killer cell cytotoxicity, BALB/c 
lymphocytes (16 x 10^ cells/ml) were incubated with K24 CPS 
(50 ^ig/ml) and/or Mur IL-2 (50U/ml) in 4ml 10% FCS-RPMI 
for 48 h at 37«C in humidified 5% CO� . Effector cells (1 x 10 
cells/ml) were added to the target WEHI-164 cells at effector-
to-target ratio of 25:1. After 24-h incubation at 37®C, the cells 
were washed and stained with neutral red. The dye uptake by 
target cells was determined by measuring the absorbance at 
540nm after lysing the cells in 1% SDS solution. The results 
were expressed as the % cytotoxicity on WEHM64 cells. The 
differences between control group and treated groups were 
determined by Student's t-test. 
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Figure 7.11 The effect of K24 CPS on the in vivo induction of 
lymphokine-activated killer cell cytotoxicity. On day 1-7，6 
BALB/c mice were injected i.p. with K24 CPS (50^ig/0.2ml 
PBS/mouse/day). On day 8，BALB/c lymphocytes (16 x 10 
cells/ml) were incubated with K24 CPS (50 jig/ml) and/or Mur 
IL-2 (50U/ml) in 4ml 10% FCS-RPMI for 48 h at 37 C in 
humidified 5% CO2. Effector cells (1 x 10^  cells/ml) were 
added to the target WEHI-164 cells at effector-to-target ratio 
of 25:1. After 24-h incubation at 37«C, the cells were washed 
and stained with neutral red. The dye uptake by target cells 
was determined by measuring the absorbance at 540nm after 
lysing the cells in 1% SDS solution. The results were expressed 
as the % cytotoxicity on WEHI-164 cells. The differences 
between control group and treated groups were determined by 
Student's t-test. ***:P<0.0005 and ****:P<0.00005. 
116 -
level of TNF-a of different groups of mice injected i.v. with different 
dose were determined by L929 assay as mentioned in the Method 
section. 
The result showed that i.v. injection of K24 CPS could elicite the 
endogenous production of TNF-a in a dose dependent manner rearch 
maximum at K24 CPS dose of lO^g/mose and the endogenous 
production of TNF-a decreased when K24 CPS dose rearch 
lOO i^g/mouse (Fig.7.12a). The concentration ofTNF-a ofthe sera was 
detected by TNF-a ELISA test kit (Fig.7.12b). 
7.7 The effect ofK24 CPS on the endogenous TNF-a 
production and EAT growth in vivo 
K24 CPS could induce endogenous TNF-a production in serum and 
tumour sited of EAT-bearing mice. The EAT growth was greatly 
suppressed after the i.v. injection ofK24 CPS into the mice (Table7.1). 
The endogenous induction ofTNF-a by K24 CPS is probably one ofthe 
contributing factors for the suppressive effect on the EAT growth in 
vivo, since TNF-a could be detected in the sera and peritoneal tumour 
sites shortly after i.v. injection ofK24 CPS into EAT-bearing mice. 
Moreover, it was found that K24 CPS could not exert any suppressive 
effect on the EAT cells in vitro at the cell density of 1 x 10^ cells/well 
(Fig.7.13). Therefore, it seems likely that the antitumour activity ofK24 
CPS may be mediated through the activation of the host immune 
components rather than direct cytotoxicity on the tumour cells. When 
compared to the result in Fig.6.1 where the cell density was 1 x 104, the 
results indicated that the cytostatic effect of K24 CPS was determined 
by the K24 CPS-to-cell number ratio employed in the assay, such that 
suppression of EAT growth was observed at high K24 CPS-to-cell 
number ratio. 
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Figure 7.12a The stimulatory effect ofi.v. injection ofK24 CPS 
on the endogenous tumour necrosis factor- a (TNF- a) 
production of BALB/c mice. 5 BALB/c mice was injected i.v. 
with different dose of K24 CPS in 0.2ml PBS. After 1.5 h， 
serum were collected from the mice by cardiac puncture. 50^1 
of serum from mice treated with different dose of K24 CPS 
were transferred to L929 cells which have been seeded for 24h. 
After 24h incubation at 37^C, the cells were washed and 
stained with neutral red. The dye uptake by L929 cells was 
determined by measuring the absorbance at 540nm after 
lysing the cells in 1% SDS solution. The % cytotoxicity was 
calculated and tumour necrosis factor- a (TNF- a) 
concentration was found from tumour necrosis factor- a (TNF-
a) standard curve. 
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Figure 7.12b The stimulatory effect of i.v. injection of K24 
CPS on the endogenous tumour necrosis factor- a (TNF- a) 
production of BALB/c mice. 5 BALB/c mice was injected i.v. 
with different dose of K24 CPS in 0.2ml PBS. After 1.5 h， 
serum were collected from the mice by cardiac puncture. 50^1 
of serum from mice treated with different dose of K24 CPS 
were determined by TNF- a ELISA test kit. Tumour necrosis 
factor- a (TNF- a) concentration was found from tumour 
necrosis factor- a (TNF_ a) standard curve. 
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Table 7.1 The effect ofi.v. injection ofK24 CPS on the serum 
TNF-a level ofEAT-bearing BALB/c mice. 
TNF-a Concentration (ng/ml) 
Treatments S ^ Ascitic fluid % Suppression of 
EAT growth 
PBS 0.003846 undetectable --
K24 CPS 2 .591977 0.084415 37.3009%±5.6585%* 
LPS 8.093218 0.001223 42.5693%±7.2534%** 
BALB/c mice in groups of 10 were inoculated i.p. with 1 x 10^ 
EAT cells in 0.2 ml PBS on day 0. On day 6，each mouse was 
injected i.v. with 10 i^g K24 CPS，LPS as positive control in 
0.2 ml PBS of0.2 ml PBS alone as control. Blood was collected 
from four mice of each group by cardiac puncture to obtain 
serum and the ascitic fluid was collected from the peritoneal 
cravity 1.5 h after the injection. TNF-a concentration in the 
pooled sera and ascitic fluids were determined by L929 assay 
using recombinant murine TNF-a as standard. The 
suppression of EAT growth was determined with the 
remaining six mice on day 7. EAT cells in each mouse were 
harvested and counted. Results were expressed as mean 士 S>D. 
The differences between control and treatment groups were 
determined by the Student's t-test. *: P<0.03; **: P<0.009 
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Figure 7.13 The in vitro cytostatic effect of K24 CPS on EAT 
growth. 1 X 10^ EAT were co-cultured with K24 CPS in 
different concentrations in the wells of 96-well plate. After 42-
h incubation, the cultured cells were pulsed with 0.5M,Ci/well 
3H-TdR and the radioactivity incorporation was determined. 
Results were expressed as % Suppression. 
% Suppression = [(CPMc�„tr�rCPMK24CPs)/CPMc�„trJ x 100% 
where CPM,,„troi is the mean count per minute of the 
control group and CPMK24 cps is the mean count per minute of 
the K24 CPS-treated group. 
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8. The Immunorestorative Activities of K24 CPS 
8.1 The in vivo Immunorestorative Activities ofK24 CPS in 
EAT-bearing Mice 
As shown in Fig.8.1, i.p. injection of K24 CPS could restore the 
supressed T cell mitogenic response in EAT-bearing BALB/c mice, both 
the splenocytes from K24 CPS-treated EAT-bearing and normal 8-8 
week-old BALB/c mice showed similar stimulation index (S.I.) in 
response to Con A whereas the splenocytes from untreated EAT-bearing 
BALB/c mice exhibit low S.I. in response to Con A. 
For B cell resonse, as shown in Fig.8.2, i.p. injection ofK24 CPS could 
partially restore the supressed B cell mitogenic response in EAT-bearing 
BALB/c mice, the splenocytes from K24 CPS-treated EAT-bearing 
BALB/c mice showed higher stimulation index (S.I.) than that from 
untreated EAT-bearing BALB/c mice in response to LPS. 
In vitro mitogenic assay is a non-specific immune reaction and has 
frequently been used as an immune parameter to investigate the 
reposiveness oflymphocyte.These result suggested that K24 CPS could 
exhibit an in vivo immunorestorative activity on depressed immune 
response in tumour-bearing mice. 
8.2 The in vitro Immunorestorative Activities ofK24 CPS in 
Mice bearing 10-day-old-EAT 
Splenocytes fromlO-day-old-EAT-bearing BALB/c mice were co-
cultured with or without K24 CPS in different concentrations. K24 CPS 
could significantly restore the depressed mitogenic response of 
splenocytes of tumour-bearing mice when compared to the cultured 
splenocytes without K24 CPS (Fig.8.3). 
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Figure 8.1 BALB/c mice were divided in groups of five and 
each injected i.p. with K24 CPS, PBS as control or none as 
normal on day -2 to 2. On day 0，BALB/c mice of K24 CPS-
treated group and control group were injected i.p. with 10^ 
EAT cells in 0.2ml PBS/mouse. On day 7，5 x 10' murine 
splenocytes ofthe three groups were co-cultured with Con A in 
different concentrations respectively. After 42-h incubation, 
the cultured cells were pulsed with 0.5jiCi/well 3H-TdR and the 
radioactivity incorporation was determined. Results were 
expressed as mean S.I. 土 S.D. 
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Figure 8.2 BALB/c mice were divided in groups of five and 
each injected i.p. with K24 CPS, PBS as control or none as 
normal on day -2 to 2. On day 0，BALB/c mice of K24 CPS-
treated group and control group were injected i.p. with 10^  
EAT cells in 0.2ml PBS/mouse. On day 7，5 x 10^ murine 
splenocytes of the three groups were co-cultured with LPS in 
different concentrations respectively. After 42-h incubation, 
the cultured cells were pulsed with O-S^Ci/well ^ - T d R and the 
radioactivity incorporation was determined. Results were 
expressed as mean S.I. 土 S.D. 
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Figure 8.3 BALB/c mice were divided in groups of five and 
each injected i.p. with 10^  EAT cells in 0.2ml PBS/mouse or, 
PBS as control. After 10 day, 5 x 10^  murine splenocytes of the 
each groups were co-cultured with K24 CPS in different 
concentrations respectively. After 42_h incubation, the 
cultured cells were pulsed with 0.5^Ci/well ^ - T d R and the 
radioactivity incorporation was determined. Results were 
expressed as mean S.I. 土 S.D. 
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9. The effect of K24 CPS in vitro induction of Murine 
Bone Marrow Cells Proliferation and Differentiation 
9.1 The effect of K24 CPS in vitro induction of Murine Bone 
Marrow Cells Proliferation 
In the bone marrow cell proliferation assay, BALB/c bone marrow cells 
were obtained from femur by Ficoll-paque gradient centrifugation and 
cultured with K24 CPS or murine IL-3 for 3 days. For control group, the 
cells were cultured in culture medium only. The cultured cells were 
pulsed with 3H-TdR for one day. Incorporation of 3H-TdR was 
determined by liquid scintillation counter. Reults were expressed as 
Stimulation Index (S.I.). 
Murine IL-3 stimulated the proliferation of murine bone marrow cells in 
a dose-dependent fashsion and acted as a positive control (Fig.9.1). K24 
CPS exhibited stimulation of bone marrow cell proliferation in a dose-
dependent manner, and showed the strongest stimulation of SI of 9 at 
concentration of 50jig/ml (Fig.9.2). 
9.2 The effect of K24 CPS in vitro induction of Murine Bone 
Marrow Cells Differentiation 
In the bone marrow cell differentiation assay, the bone marrow cells 
were extracted and cultured as mentioned in the proliferation assay. 
After 3day incubation, the cells were fixed on a slide by cytospin. The 
cells were morphologically stained by Hemacolor Rapid Blood Smear 
Staining Set. The number of differentiated and undifferentiated cells 
were counted and the results were expressed as %differentiation. 
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Figure 9.1 The effect of interleukin-3 (IL-3) on the In vitro 
proliferation of murine bone marrow. BALB/c bone marrow 
cells were isolated and co-cultured in the presence and absence 
of IL-3 in the wells of 96-well flat-bottomed plate at 1 x 10^  
cells/well in a volume of 0.2ml at 37®C in humidified 5% CO� 
for 72h. The cells were then pulsed with 0.5^Ci/well ^H-TdR 
for 24h. The radioactivity incorporation was determined. 
Results were expressed as mean S.I. ± S.D. 
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Figure 9.2 The effect of K24 CPS on the In vitro proliferation 
of murine bone marrow. BALB/c bone marrow cells were 
isolated and co-cultured in the presence and absence of K24 
CPS in the wells of 96-well flat-bottomed plate at 1 x 10^  
cells/well in a volume of 0.2ml at 37®C in humidified 5% CO� 
for 72h. The cells were then pulsed with 0.5piCi/well ^H-TdR 
for 24h. The radioactivity incorporation was determined. 
Results were expressed as mean S.I. 土 S.D. 
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Fig.9.3 showed the morphology of normal bone marrow cells. It had 
relatively small size, high nucleus to cytoplasm ratio and no vacuole. 
Fig.9.4 showed the morphology of cells incubated in murine IL-3 at 400 
U/ml for 3 days. It had macrophage-like chacteristics such as larger size, 
lower nucleus to cytoplasm ratio and increased number of vacuoles. 
Fig.9.5 showed the morphology of cells incubated in K24 CPS at 50 and 
100 ^ig/ml for 3 days. It showed similar macrophage-like chacteristics as 
that observed in the murine IL-3-induced differentiatied bone marrow 
cell with larger size, lower nucleus to cytoplasm ratio and increased 
number of vacuoles. 
Murine IL-3 which acted as a positive control at concentrations of 200 
or 400 U/ml showed differentiation-inducing activity, about 35% ofthe 
bone marrow cells were differentiated with macrophage-like 
characteristics (Fig.9.6). K24 CPS induced differentiation of about 75% 
ofbone marrow cells at concentrations of 50 and 100 p,g/ml (Fig.9.7). 
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Figure 9.3 The normal murine bone marrow cells. B A O / c 
bone marrow cells were isolated and co-cultured in the wells of 
96-well flat-bottomed plate at 1 x 10^ cells/well in a volume of 
0 2ml at 37�C in humidified 5% CO, for 72h. The cells were 
siained using Hemacolor Rapid Blood Smear stainmg set 
(Merck). 
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Fi2ure 9.4 The effect of IL-3 on the in vitro differentiation of 
murine bone marrow cells. BALB/c bone marro^ cell, were 
isolated and co-cultured in the presence o f I L - 3 (400 U/ml) m 
the wells of 96-well flat-bottomed plate at 1 x 10^ cells/well m a 
volume of 0.2ml at 37�C in humidified 5% CO, for 72h The 
differentiation inducing activity of IL-3 were evaluated by 
staining using Hemacolor Rapid Blood Smear stainmg set 
(Merck). 
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Figure 9.5 The effect ofK24 CPS on the in vitro differentiation 
of murine bone marrow cells. BALB/c bone marrow cells were 
isolated and co-cultured in the presence of K24 CPS (lUU 
na/ml) in the wells of 96-well flat-bottomed plate at 1 x l O 
cells/well in a volume of 0.2ml at 37�C in h u m i d i f i e d 5% CO, 
for 72h. The differentiation inducing activity ofK24 CPS were 
evaluated by staining using Hemacolor Rapid Blood Smear 
staining set (Merck). 
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Figure 9.6 The effect of IL-3 on the in vitro differentiation of 
murine bone marrow cells. BALB/c bone marrow cells were 
isolated and co-cultured in the presence ofIL-3 in the welIs of 
96-well flat-bottomed plate at 1 x 10^  cells/well in a volumeof 
0.2ml at 37«C in humidified 5% CO, for 72h. The 
differentiation inducing activity of IL-3 were evaluated by 
staining using Hemacolor Rapid Blood Smear stammg set 
(Merck) and counting the number of differentiated ^cdls. 
Results were expressed as % differentiation ± S.D. •  
P<0.0005 
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Figure 9.7 The effect ofK24 CPS on the in vitro differentiation 
of murine bone marrow cells. BALB/c bone marrow cells were 
isolated and co-cultured in the presence of Ji24 CPS in the 
wells of 96-well flat-bottomed plate at 1 x 10^ cells/well m a 
volume of 0.2ml at 37�C in humidified 5% CO, for 72h. The 
differentiation inducing activity ofK24 CPS were evaluated by 
staining using Hemacolor Rapid Blood Smear stainmg set 
(Merck) and counting the number of differentiated ^ceUs. 
Results were expressed as % differentiation 土 S . D . 磁 : 
P<0.0005 
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10. Conclusions and Future Perspectives 
In the research project, the immunopharmacological properties ofK24 
CPS were studies, both in vitro and in vivo. K24 CPS was found to be a 
bioactive polysaccharide which can trigger and enhance the immune 
response to tumour (Fig.10.1). K24 CPS has potent mitogenic activity 
for splenocytes. Besides, K24 CPS exhibit potent anti-tumour activity 
and can trigger the host cell-mediated anti-tumour responses such as the 
activation of macrophages, LAK cells and NK cells. Moreover, K24 
CPS can also stimulate macrophages to release nitric oxide and 
cytokines such as IL-1 and TNF-a with anti-tumour activity. In 
addition, K24 CPS can induce the proliferation and differentiation of 
murine bone marrow cells and stmulate haematopoiesis in vitro. 
The structure ofabioactive compound may have profound influence on 
its biological and immunopharmacological activities. For example， 
linear p-l,3-glucan are effective in inducing PMN cytotoxicity than that 
of p-l,4-glucan with mannosyl branching (Morikawa et al., 1985). In 
addition, the anti-complementary activities ofpolysaccharides are found 
to relate to their acidity, molecular weight and hydroxyl groups (Lien 
and Gao, 1990). Therefore, further investigation of the structure-
function relationship ofK24 CPS is necessary in order to increase our 
understanding ofthe action mechanisms. 
The complement system plays an important role in our immune defence 
against inflammation and infections (Porter and Reid, 1978). Recently, a 
number of polysaccharides have been shown to possess anti-
complementary activity (Gao et al., 1988; Yamada, 1989; Yamada et al., 
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Figure 10.6 Schematic diagram showing the hypothetical 
mechanisms of immunostimulating ang anti-tumour activities 
of K24 CPS 
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complement system via the classical and/or alternative pathway is 
obviously an intriguing aspect that is worth of further investigation. 
Although K24 CPS can act as a mitogen for lymphocytes in vitro and 
co-mitogen for the T lymphocyte response in tumour-bearing mice, 
nevertheless, the precise T lymphocyte subsets being affected have not 
been identified. Therefore, the investigation ofthe stimulating effects of 
K24 CPS on T helper ( ¾ ) and T suppressor (Ts) cell functions may 
provide a useful means in the better understanding of immune 
regulation. 
Results from the present study indicate that K24 CPS can effectively 
induce the differentiation ofmurine bone marrow cells in vitro. It would 
be of great interest to examine whether K24 CPS can effectively induce 
the differentiation ofmyeloid leukaemia cells and synergize with other 
biological response modifiers in the induction of tumour cell 
differentiation. In addition, the ability of K24 CPS to stimulate the 
terminal differentiation of other types of tumour cells requires further 
investigation. If the induction of reversal of malignancy to normal 
and/or mature form is promising, the induction ofcell differentiation by 
natural-occuring polysaccharides will provide a new strategy in the 
treatment of certain cancer (e.g. leukaemia) in the future and it may 
widen the clinical application ofK24 CPS. 
Adoptive immunotherapy of cancer involves the transfer of activated 
immune cells that can mediate direct or indirect anti-tumour effects in 
vivo. Preclinical studies in murine tumour models have demonstrated 
that cytokines, used alone or in combination with adoptive 
immunotherapy, can induce significant anti-tumour response (Hillman et 
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al., 1992). The anti-tumour activities ofK24 CPS have been found to be 
mediated through activation of the host immune system such as the 
induction ofthe anti-tumour cytotoxic cells e.g. macrophages, NK cells, 
LAK cells, NK cells and the release of the anti-tumour cytokines e.g. 
IL-1, TNF-a. It is conceivable that combined effects of cell-mediated 
immunity and cytokine-mediated immunity will result in greatly 
enhanced anti-tumour activity in vivo. Therfore, the application of K24 
CPS may have therapeutic advantages over conventional methods of 
cancer since K24 CPS can activate cytotoxic effector cells and induce 
cytokine production. In addition, clinical trials involving adoptive 
immunotherapy with TILs are currently in progress (Kariya et al., 1991; 
Mizutani and Yoshida, 1991). I f the cell subpopulation in TILs with 
potent tumour reactivity activated by K24 CPS can be identified and 
selectively expanded, this cell population can also be used for adoptive 
immunotherapy. 
Most chemotherapeutic drugs (e.g. MTX，5-FU, CY etc) act by direct 
cytotoxic effect but they also exhibit potent immunosupressive activity 
at high dosages (Chu et al., 1988; Mizushima et aL, 1982). On the other 
hand, the anti-tumour activity ofimmunostimulating K24 CPS is mainly 
mediated indirectly through the enhancement of immune responses and 
directly through the alteration of the level of c-jun, phosphotyrosine and 
phosphothreonine of tumour cell e.g. EAT cell. Therefore, the 
combination of these two modalities, chemoimmunotherapy, will take 
advantage oftheir different mechanisms ofaction. Some tumours show 
a good initial response to chemotherapy, reducing the tumour burden, 
but they often recur in the form of drug-resistant variants. The 
application ofimmuntherapy may produce an additive/synergistic anti-
tumour activity in vivo. Chemotherapy reduces the tumour size and 
allows immunotherapy，elicited by the use ofK24 CPS, to fonction in a 
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minimal residual disease setting. Besides, the traditional 
chemotherapeutic drugs, monoclonal antibodies which can deliver anti-
cancer agents such as cytotoxic drugs, toxins or radionuclides) to the 
specific tumour target have great potential in cancer therapy. The 
combined use of this kind of monoclonal antibodies or immunotoxins 
and K24 CPS can also facilitate tumour destruction. 
Polysaccharide preparations from sea algae (SAE) (Nakashima et aL, 
1987) and PSK (Hirose et al., 1987; Tochikura et al., 1987) have been 
found to inhibit the activity of human immunodeficiency virus (HIV) 
reverse transcriptase, thus inhibiting virus replication in vitro. Whether 
K24 CPS have any anti-HIV effect is worth of further investigation. It is 
because polysaccharides with anti-viral effect and immunopotentiating 
properties will be potentially an effective and ideal therapeutic modality 
for the treatment of AIDS. 
The results presented in this thesis clearly show taht K24 CPS possesses 
immunomodulatory and anti-tumour activities both in vitro and in vivo. 
Since traditional modalities used in cancer treatment often have many 
undesirable side effect, therefore, the isolation and characterization of 
potent immunomodulatory and anti-tumour K24 CPS may open a way 
for more effective treatment of cancer. Nevertheless, detailed 
characterization and even structural modifications of the bioactive 
polysaccharides by enzymatic and chemical methods may be necessary 
for the developmant ofmore specific and potent compounds with anti-
tumour activity. In addition, further analysis of the molecular 
mechanisms by molecular biology e.g. regulation of the transcription 
and translation of gene and cellular mechanisms e.g. intracellular signal 
transduction such as intracellular calcium, protein kinase C, cyclic 
AMP, etc. of the anti-tumour activities of K24 CPS may provide a more 
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rational scientific basis for better utilization of K24 CPSin canceer 
treatment. Finally, it is hoped the further characterization of K24 CPS 
may provide an alternative way for cancer treatment. 
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